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ABSTRACT 
 
Trypanosoma cruzi, a parasitic protozoan, is the etiologic agent of Chagas disease. Chagas 
disease is the most common cause of congestive heart failure related deaths among young 
adults in the endemic areas of South and Central America and Mexico. It has also become 
an important health issue in the United States and Europe due to large scale migration of 
Latin Americans over the last few decades. No vaccines are currently available until now. 
In this study, we tested the vaccine efficacy of two antigen candidates against T. cruzi 
infection and disease in a mouse model. The use of TcVac1 (TcG2, TcG4, T cruzi antigen 
encoding plasmids, interleukin-12 [IL-12] and granulocyte-macrophage colony-stimulating 
factor [GMCSF] encoding plasmids as genetic adjuvants) anti T. cruzi candidate vaccine 
injected intramuscularly has been previously reported in mice with very encouraging 
results. Here we evaluated the comparative protection conferred by TcVac1 when 
administrated intramuscular (IM) versus an intradermal/electroporation (IDE) vaccination 
protocol. Twelve BALB/c mice per group were vaccinated four times fifteen days apart. 
Half the animals (n=6) from each treatment were sacrificed two weeks after the last 
immunization for pre-infection vaccine efficacy evaluation, and the second half (n=6) was 
sacrificed 60 days post-infection (dpi) with T.cruzi Trypomastigotes (Sylvio X10/4 strain). 
Immune response was assessed through anti-TcG2 and TcG4 T. cruzi antigens.TcVac1 
induced a strong IgG response (IgG2b>IgG1) that was significantly expanded post-
infection, and moved to a nearly balanced IgG2b/IgG1 response in chronic phase. High IgG 
titers with IgG2 predominance in response to T. cruzi infection specific serum antibodies 
with an Enzyme Linked Immunosorbent Assay (ELISA) and lymphocyte activation against 
the studied antigens was evaluated through a lymphocyte proliferation assay. We found that 
IDE induced significantly larger surges of IgG antibodies including subtypes IgG1, IgG2a 
and IgG2b, during the pre- and post-infection periods for the two antigens used in the 
experiment. The ratio of antibodies IgG2b/IgG1 was >1 for TcG2 antigen in the pre-
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infection period in both administration routes. However for the TcG4 antigen the ratios 
were opposite for animals belonging to different administration routes<1 for IDE and >1 
for IM. During the post infection period for both treatments IgG2b/IgG1 ratio was always 
<1. Suggesting, as previously reported that a switch from Th1 to Th2 type immune 
response occurs in vaccinated/infected animals. During the Lymphocyte proliferation 
assays we observed that both antigens were able to induce lymphocyte proliferation during 
the pre-infection period. However, we observed that animals from the IDE group induced 
more proliferation than IM mice group when TcG4 was used to activate the cells, which 
was also observed during the post-infection phase of the experiment. No animals died due 
to infection, vaccinated mice appeared to have healthier status than the control animals. 
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RESUMEN 
Trypanosoma cruzi, un protozoario, es el agente etiológico de la enfermedad de Chagas. La 
enfermedad de Chagas es la causa más común de muertes relacionadas insuficiencia 
cardiaca congestiva entre los adultos jóvenes en las áreas endémicas de Sudamérica, 
Centroamérica y México. También se ha convertido en un problema de salud importante en 
los Estados Unidos y Europa debido a la migración a gran escala de los latinoamericanos en 
las últimas décadas. Hasta ahora no existen vacunas disponibles. En este estudio, hemos 
probado la eficacia de la vacuna de dos antígenos contra la infección de T. cruzi y la 
enfermedad en un modelo murino. El uso de TcVac1 (TcG2, TcG4, el antígeno de T cruzi 
que codifica plásmidos, interleucina-12 [IL-12] y factor estimulante de colonias 
granulocitos-macrófagos [GMCSF] que codifican plásmidos como adyuvantes genéticos) 
vacuna candidata contra T. cruzi inyectada por vía intramuscular ha sido probad 
anteriormente en ratones con resultados muy alentadores. Aquí se evaluó la protección 
conferida por la comparativa TcVac1 administrada via intramuscular (IM) contra un 
protocolo de vacunación electroporación/intradérmica (IDE). Se vacunaron doce ratones 
BALB/c por grupo, cuatro veces, con quince días de diferencia. La mitad de los animales 
(n=6) de cada tratamiento, se sacrificaron dos semanas después de la última inmunización 
para la evaluación de la eficacia de la vacuna en la pre-infección y la segunda mitad (n=6) 
se sacrificaron 60 días después de la infección (dpi) con T. cruzi tripomastigotes (cepa 
Sylvio X10/4). La respuesta inmune fue evaluada a través de antígenos anti-TcG2 y TcG4 
T. cruzi .TcVac1 indujo una fuerte respuesta de IgG (IgG2b>IgG1) que se expandió de 
manera significativa después de la infección, y se mudó a una respuesta equilibrada 
IgG2b/IgG1 en fase crónica. Se observaron títulos altos de IgG con predominancia de IgG2 
en respuesta a los anticuerpos séricos específicos de infección por T. cruzi en un ensayo por 
inmunoabsorción ligado a enzimas (ELISA), la activación de linfocitos frente a los 
antígenos estudiados se evaluó a través de un ensayo de proliferación de linfocitos. Se 
encontró que el IDE induce oleadas significativamente mayores de anticuerpos IgG 
incluyendo subtipos IgG1, IgG2a e IgG2b, durante los períodos pre y post-infección para 
los dos antígenos utilizados en el experimento. La proporción de anticuerpos IgG2b/IgG1 
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fue>1 para el antígeno TcG2 en el período previo a la infección en ambas vías de 
administración. Sin embargo para el antígeno TcG4 la proporción fue opuesta para los 
animales que fueron vacunados con diferentes vías de administración <1 para IDE y >1 
para IM. Durante el período posterior a la infección para ambos tratamientos la proporción 
de IgG2b/IgG1 fue siempre <1. Estos resultados sugieren que como se informó 
anteriormente, que un cambio de la respuesta inmune de tipo Th1 a Th2 se produce en los 
animales vacunados/infectados. Durante los ensayos de proliferación de linfocitos se 
observó que ambos antígenos fueron capaces de inducir la proliferación de linfocitos 
durante el período de pre-infección. Sin embargo, se observó que los animales del grupo 
IDE indujeron una mayor proliferación que en los ratones del grupo IM cuando se utilizó 
TcG4 para activar las células, lo que también se observó durante la fase posterior a la 
infección del experimento. No hubo muerte de animales durante la infección, los ratones 
vacunados parecían más saludables que los animales control. 
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1. INTRODUCTION 
1. Chagas disease: 
Chagas disease is named after Carlos Chagas, the pioneer researcher who first 
described it in 1909 (Chagas, 1909). Existing only on the American continent, the disease is 
caused by a flagellate parasite, Trypanosoma cruzi, and is mainly transmitted to humans by 
blood-sucking triatomine bugs. Chagas disease has two successive phases, acute and 
chronic. The acute phase lasts 6-8 weeks. Once the acute phase abates, most of the infected 
patients recover an apparent healthy status, where no organ damage can be demonstrated by 
clinical diagnosis methods. The infection can only be verified by serological or 
parasitological tests. This form of the chronic phase of Chagas disease is called 
indeterminate form. Most patients remain in this form of the disease. However, after several 
years of this phase, 20-35% of the infected individuals will develop irreversible lesions of 
the autonomous nervous system in the heart, oesophagus, colon, and peripheral nervous 
system, and it lasts for the rest of the infected individual's life. Chagas disease represents 
the first cause of cardiac lesions in young, economically productive adults in the endemic 
countries in Latin America (Coura et al., 1983, 1985; Pereira et al., 1985). 
 
1.1. Clinical manifestations of the disease: 
An important point in the identification of Chagas disease was the observation of an 
ocular edema known as Romaña’s sign. Romaña’s sign is a pathognomonic early sign of 
Chagas disease a one side severe conjunctivitis and swelling of the eye lid, inflammation of 
the tear gland and swelling of regional lymph glands caused by the entry of T. cruzi 
parasite. The sign has proved of great value in identification the infection in its acute phase. 
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1.2. First Evidence of American Trypanosomiasis in Latin America: 
The first report of American human Trypanosomiasis was discovered Segovia in El 
Salvador in 1913 (Segovia, 1913), In Panama in 1931, the presence of the disease was 
proven with the report of 19 human cases in the area of the Panama Canal, De Leon in 1935 
highlighted the importance of this disease in this country (León Gómez et al., 1960), In 
1949, the first native case of the disease was described in Nicaragua, and as recently as in 
1969 Fray Bernadini de Schagen reported that homes were infested by vectors described as 
“poisonous bloodsucking insects like cockroaches.” In Mexico in 1928, Hoffman described 
the great abundance and domiciliation of Triatoma dimidiata in Chiapas and Veracruz. 
In1938 Bernal Flandes published on transmitter insects and trypanosomatides in Veracruz, 
and in 1940, Palomo Eroso described two other new cases in Yucatan. It was only in 1972 
that the first formal identification of the disease was carried out with reports by Eugenio 
Palomo and Luis Mazzotti (Symposium: National Academy of Medicine, 1975). 
 
 
 
 
 
Figure 1: First case of Chagas disease in Bolivia, reported in a girl aged 14 in Capinota, Department of Cochabamba, 
Bolivia. 
 
1.3. Chagas disease life cycle and invasion mechanism: 
Trypanosoma cruzi, the protozoan parasite, has a digenetic life cycle involving both 
vertebrate and invertebrate hosts within which developmental stages of the parasite arise 
(Fig. 2). As an obligate intracellular parasite in the vertebrate host, intracellular localization 
is critical for establishment and maintenance of T. cruzi infection. Host cell invasion is 
accomplished by metacyclic trypomastigotes, which is highly specialized, non-dividing 
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forms of T. cruzi that can penetrate a wide variety of mammalian cell types. Once inside the 
host cell, trypomastigotes undergo a developmental process that culminates in the 
formation of replicative amastigotes that proliferate in the host cell cytoplasm for 5–6 days 
until they occupy most of the cell volume. At this stage, amastigotes division ceases and 
differentiation to trypomastigotes occurs followed by rupture of the host cell plasma 
membrane (Costales and Rowland, 2007) releasing trypomastigotes that disseminate 
infection. 
 
 
Figure 2: Trypanosoma cruzi life cycle. Metacyclic Trypomastigotes arising from Epimastigotes in the reduviid host are 
transmitted to mammalian host in the feces of the insect vector. Inside the host, Trypomastigotes invade cells and are 
rapidly targeted to a lysosome-derived vacuole. Within the vacuole, trypomastigotes begin the transformation to 
amastigotes (2–8 h) after which the vacuole is gradually disrupted and parasites localize to the host cell cytoplasm (8–16 
h). Cytosolic amastigotes begin to divide at 24 hrs. post-invasion and continue to divide every 12 hrs for 5–6 days, then 
differentiate back into trypomastigotes, rupture the host cell, enter the host circulation and disseminate infection. 
 
Cell lysosomes are exploited by T. cruzi as the gateway to the host cell cytoplasm, electron 
micrographs revealed that shortly after invasion, T. cruzi trypomastigotes are housed within 
tight-fitting membrane bound vacuoles that fuse with host cell lysosomes (de Carvalho and 
de Souza, 1989; de Meirelles Mde et al., 1987; Nogueira and Cohn, 1976; Tanowitz et al., 
1975). As intracellular infection progresses, Trypomastigotes differentiate into Amastigotes 
which divide in the host cell cytoplasm (Ley et al., 1990; Nogueira and Cohn, 1976) the 
parasitophorous vacuole was rapidly acidified and that acidification was essential for 
vacuole membrane disruption and release of parasites into the cytoplasm (Ley et al., 1990). 
Immune protection against Trypanosoma cruzi induced by TcVac1 vaccine in a murine model using an intradermal/electroporation protocol  
4 
These observations coincided with the discovery of a secreted T. cruzi lytic activity (TC-
TOX) that is released into the lumen of the parasitophorous vacuole where it is optimally 
active at low pH (Andrews and Whitlow, 1989). 
 
1.4. Modes of transmission of Chagas disease: 
1.4.1. Transmission through Vectors: 
 
On the basis of country wide cross-sectional surveys, it was estimated that the 
overall prevalence of human T. cruzi infection in the 18 endemic countries has reached 17 
million cases. 
It was estimated that 100 million people (25% of all the inhabitants of Latin America) were 
at risk of contracting T. cruzi infection (UNDP/WORLDBANK/WHO, 1991). The 
originally endemic area with vectorial transmission in the human domicile comprised 18 
countries with higher T. cruzi infection rates in the regions infested by Triatoma infestans 
(Southern Cone countries) and Rhodnius prolixus (Andean countries and Central America), 
which were the triatomine species are adapted to the human domicile. 
 
1.4.2. Transmission through blood transfusion: 
 
The transmission of Chagas disease via blood transfusion is a real threat even for 
countries where the disease is not transmitted by vector, such as the USA and Canada, 
where cases of acute Chagas disease have been documented (Grant et al., 1989; Kirchhoff 
et al., 1987; Nickerson et al., 1989). In 1986, Puebla, México have showed 17.5% positive 
infected cases with T. cruzi from 200 tested samples (Velasco Castrejón and Guzmán 
Bracho, 1986). The prevalence rates of T. cruzi infection in blood varied between 1.3% and 
51.0%, these rates were much higher than those of hepatitis or HIV infection. Transmission 
through transfusion could be prevented if blood is screened by serology and positive units 
are discarded. 
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1.4.3. Transmission via oral: 
 
The oral transmission is the fact that several persons are affected simultaneously 
pointing to the occurrence of a common source outbreak through contaminated food. For 
the prevention of this transmission is based on surveillance, prevention, and management 
contaminated food as recommended by a group of experts convened by the PAHO in 
Brasili (OPS/DPC/CD/CHA, 2006). This route of transmission was established and 
documented (Shikanai-Yasuda et al., 1991; Valente et al., 1999; Camandaroba et al., 2002; 
Rodríguez-Morales, 2008). One of the most documented cases is due to the ingestion of 
açai juice and is concentrated in the States of Pará and Amapá, where the production of this 
fruit is intensive. 
1.4.4. Other ways of transmission: 
 
Transfusional transmission:  
 
which is considered to be the second most important way of spreading the infection 
in endemic and non endemic areas, this transmission route mainly depends on the presence 
of the parasite in the blood and the immunological state of the receptor, and it was detected 
that the parasite is viable at 4ºc for a period of time from 18 to 250 days (Schmunis and 
Cruz, 2005). 
Congenital transmission:  
 
The number of cases of congenital Chagas disease has been estimated about 14,385 
per year in Latin America, about 66 to 638 per year in the United States, and about 20 to 
183 per year in Europe (Pan American Health Organization, 2006), congenital transmission 
of Chagas disease may occur during any phase of maternal disease. During the first 
trimester of pregnancy (weeks 1–12), transmission is probably rare. Maternal blood supply 
becomes continuous and diffuse in the entire placenta only after the 12th week of gestation. 
Therefore, transmission of blood parasites probably occurs most frequently during the 
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second and third trimesters of pregnancy (prenatal transmission) and perhaps also closer to 
delivery and during labor (perinatal transmission) through placental breaches/tears (Carlier 
and Truyens, 2010, 2012). 
 
Blood banking transmission: 
 
Trypanosoma cruzi transmission by blood transfusion has been much extended in 
endemic areas due to the lack of controls in blood banks. Due to the persistence of the 
parasite in the patient, infected people may be responsible for parasite transmission through 
blood donation throughout their life even when they are asymptomatic and unaware of their 
infected status. In many of the endemic countries, blood transmission of Chagas disease 
strongly decreased in the 1990s after the development of the of T. cruzi-specific antibodies 
detection in blood banks (Moncayo, 2003; Schmunis, 2007; Moncayo and Silveira, 2009). 
Control of T. cruzi infection in blood banks was recently extended to non-endemic 
countries (Wendel, 2010). People who have resided for some months in endemic areas 
cannot give their blood without serological T. cruzi control. The efficiency of blood donor 
screening programs could be improved by screening only blood donors who were born in 
Latin America or who have traveled in Latin America for extended periods, using a single 
enzyme immunoassay (Appleman et al., 1993; O’Brien et al., 2007). 
 
Organ transplantation transmission: 
 
Persons receiving an organ transplant from an infected donor are also at risk for 
Chagas disease, due to immunosuppressive treatment in the organ receiver, a small number 
of parasites present in the graft were able to develop quickly. Additionally, an infected 
patient who is receiving an organ transplant may develop a high parasitemia and clinical 
signs of Chagas disease when immunosuppressive treatment is implemented before the 
graft. (Riarte et al., 1999; Altclas et al., 2005; D’Albuquerque et al., 2007; Fore´s et al., 
2007; Martin-Davila et al., 2008; Sousa et al., 2008; Kun et al., 2009). The problem also 
occurred in non-endemic countries and the impacts differed according to the transplanted 
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organ. Indeed, the consequences of heart transplantation seem much more serious than 
kidney or liver transplantation from the same donor. 
 
Laboratory accidental transmission: 
 
Investigators working in research or clinical laboratories are at risk of being 
infected with Trypanosoma cruzi through the handling of materials containing viable 
parasites (e.g., infective trypomastigotes, infective amastigotes and metacyclic 
trypomastigotes). The most frequent accidental laboratory-acquired contaminations resulted 
from needle-stick injuries during experimental infection of mice or from transmission by 
aerosol or droplets of infected materials (T. cruzi tissue culture supernatants, triatoma feces, 
and infected blood) by skin or mucosal contact (Coudert et al., 1964; Brener, 1984; Hofflin 
et al., 1987; Herwaldt, 2001). Other sources of laboratory contamination were the spraying 
of parasites by droplets or the breaking of a tube containing living parasites. In particular, 
special tubes for cryogenic preservation frequently rupture when they are thawed. 
Contamination also may occur due to a very low quantity of parasites and the parasite may 
be also present in dry droplets of infective culture or contaminated blood present on a 
bench. Epimastigotes culture is often considered to be non-infective; however, old cultures 
that are enriched in metacyclic trypomastigotes are infectious. Laboratory acquired 
contamination can be prevented by wearing gloves, a mask, by making cultures in a bio-
safe laboratory (L3 type), and by using appropriate facilities for animals. 
 
1.5. Globalization of the transmission: 
The increasing mobility of populations and the migration toward non endemic 
countries have extended the infection to these countries through blood transfusion, organ 
transplantation and the congenital form among migrants. The risk is related with the 
country of origin of the migrants and the rate of prevalence in that given country. However, 
the advances observed in control of the transmission indicate that this potential extension to 
Europe, the USA, and Canada might be transitory or decreasing. The WHO recently 
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launched the Global Network for Chagas disease elimination (GNChE) to control this 
situation. It was also reported the global dispersal of Chagas disease due to migrant South 
and Central American populations to Europe, North America, Japan, and Australia. Finally, 
the need for non endemic countries to maintain and develop an awareness of Chagas 
disease as a consequence of globalization is necessary (Schmunis and Yadon, 2010). 
 
1.6. Vector epidemiology and distribution: 
A fully understanding of the epidemiology of Chagas disease across its distribution 
was proven to be elusive and complex, and remains under intense investigation to the 
present day. The difficulty in defining the epidemiology of Chagas disease is attributable to 
several factors. Firstly, Chagas disease is a zoonosis and a variety of widely distributed 
mammals serve as reservoirs for T. cruzi. Moreover, all mammals are susceptible to 
infection. A further factor that contributes to the complexity of Chagas disease as a 
zoonosis is the variety of vectors involved, being not simply represented by a range of 
related species or genera, as is the case for all other insect vectors, associated with any 
given disease. Triatomine bugs are a subfamily of insects and across this relatively broad 
taxonomic range there are members from all groups that can harbor T. cruzi. Most 
transmission, however, is attributable to three main genera: Rhodnius, Panstrongylus, and 
Triatoma, but this diversity still represents two different tribes of the subfamily 
(Rhodniiniand and Triatomini). Furthermore, the insects vary in more than ancestry, having 
a diverse range of vertebrate host and ecological associations. The third factor that 
complicates Chagas disease epidemiology and accounts for variation in the clinical 
manifestation of the disease is the sub specific diversity of T. cruzi itself. Much work has 
been conducted over the past 40 years to elucidate the variation of T. cruzi across its 
geographical distribution and associations with hosts and vector species. In addition to 
vector transmission, a small percentage of cases are attributable to unscreened blood 
transfusions, congenital transmission, and incidences of oral transmission by contamination 
of food. In 1990, it was estimated that greater than 80% of transmission was due to vectors 
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and approximately 16% were due to blood transfusion (Schofield, 1994). The endemic 
transmission of Chagas disease in humans and wild hosts is restricted to the Americas and 
corresponds largely with the distribution of triatomine bugs approximately from latitudes 
42ºN to 46ºS (i.e., from the mid-USA to Patagonia). The triatomines constitute a subfamily 
of an otherwise predatory group of bugs, and is relatively small compared to the thousands 
of predatory reduviids. The Triatominae comprises some 140 species. This diversity is 
classified into six tribes and 19 genera. Certainly three of the most important vector species, 
Triatoma infestans, Rhodnius prolixus, and Triatoma dimidiata, have distributions across 
several countries (Abad-Franch et al., 2005) (Figure 3). 
 
Figure 3: Map of Chagas endemic regions of Central and South America showing respective associations with the 14 
most important vector species. The five most important vector species are T. infestans, R. prolixus, T. dimidiata, P. 
megistus, and T. brasiliensis. Genera are Triatoma Rhodnius, Panstrongylus and Meccus  
Most of the 140 Triatominae species occupy sylvatic ecotopes in association with their 
respective vertebrate hosts. Examples include: palm crowns, bird nests, possum lodges, 
rock piles, hollow trees, rodent nests, and bat caves. In most cases triatomine species are 
adapted to their ecotopes with little tendency to invade human habitations. Therefore, there 
are only 10-15 species of triatomines that show anthropophilic tendencies and are regularly 
implicated in disease transmission (Abad-Franch et al., 2010; Cohen and Gurtler, 2001; 
Campbell-Lendrum et al., 2007) (Figure 3). 
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1.7. Chagas disease phases: 
Chagas disease is characterized by an acute and a chronic phase of infection. In the 
acute phase most patients have the unapparent (asymptomatic) form, while in the chronic 
phase two well-defined forms of disease are distinguished: indeterminate (latent, 
preclinical) and determinate (clinical), which is subdivided into cardiac, digestive (usually 
expressed as megaesophagus and/or megacolon), and cardiodigestive forms. Chagas 
disease is clinically silent in most patients (mainly in the acute phase, but also during the 
chronic phase), and the diagnosis should be confirmed by the results of laboratory tests. 
Very often the diagnosis is made fortuitously; for example, when individuals donate blood, 
during health screening examination, during self-referral testing, and in patients with a 
strong positive family history or epidemiological antecedents. 
1.7.1. Acute phase:  
 
The acute phase of Chagas disease is observed mainly in the first or second 
decades of life. Clinical manifestations appear around (8-10) days after the penetration of 
the parasite (Rassi et al., 2000). In transfusion transmitted Chagas disease this period may 
be longer (20-40 days). The acute phase is not clinically recognized in most cases. The 
experience of those who work in endemic areas is that there is one diagnosed acute case for 
every 100 chronic patients. Romaña’s sign is the most typical sign of portal of entry of the 
parasite. It is characterized by a painless swelling of one or both eyelids of one eye, the 
eyelids turn a bluish color, and conjunctival congestion and hypertrophy of satellite lymph 
nodes (usually preauricular) frequently occur. The edema may spread to half of the face; 
sometimes dacryoadenitis and diminished conjunctival secretion are observed. Inoculation 
chagoma is another sign of portal of entry (through the skin), characterized by a 
maculonodular erythematous lesion, consistent, painless, surrounded by swelling and 
increased volume of satellite lymph nodes, more often found on open areas and sometimes 
ulcerated. Fever is a constant sign, frequently accompanied by malaise, asthenia, anorexia, 
and headache. Fever is usually higher in children, may be continuous or intermittent, and 
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the temperature may be more elevated during the afternoon. Lymph node enlargement, 
hepatomegaly, splenomegaly, and subcutaneous edema are the principal systemic signs, 
together with cardiac and neurologic alterations. Lymph node enlargement is frequent, of 
slight or moderate intensity, isolated or contiguous, with a smooth surface, painless, hard 
and non-adherent, and not fistulous. Hepatomegaly and splenomegaly are also frequent, 
with characteristics similar to that of lymph nodes. Mild to moderate leucocytosis may 
occur during the acute phase of the disease, with lymphocytosis (atypical lymphocytes), 
plasmocytosis, and relative neutropenia. Eosinophilia may be observed during the evolution 
of the disease. The mortality in the acute phase used to be around 5% of all symptomatic 
cases, often as a consequence of meningoencephalitis or myocarditis. However, nowadays 
this percentage has decreased as the result of use of specific drugs. Spontaneous cure, 
although exceptional, may occur as has been described by Zeledón et al., (1988) and 
Francolino et al., (2003). 
1.7.2. Chronic phase: 
 
The chronic phase begins (2-3) months after the initial infection when the clinical 
manifestations of the acute phase disappear (if present), and parasitemia falls to 
undetectable levels. In most cases, the chronic phase presents as an indeterminate form, 
which may evolve to the cardiac, digestive, or cardiodigestive forms after years or decades. 
The diagnosis is made by serological tests, such as indirect hemagglutination, indirect 
immunofluorescence, and ELISA, all of which have high sensitivity and acceptable 
specificity. The concept of the indeterminate form was not based on histological findings, 
but on the fact that visceral lesions could not be detected through clinical examination and 
complementary routine exams in a significant proportion of patients in the chronic phase of 
Chagas disease. An individual chronically infected with T. cruzi remains in the 
indeterminate form, generally for a period of (10-30) years. There have been few 
pathological studies focusing on individuals with the indeterminate form. Necropsy studies 
of patients who died from accidental causes revealed mild myocarditis with scattered small 
foci of interstitial infiltration by lymphocytes, macrophages, and plasma cells, together with 
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a limited reduction in the number of cardiac neurons and myenteric plexuses that are 
insufficient to produce clinical manifestations (Lopes et al., 1981). The cardiac form is the 
most serious and frequent manifestation of chronic Chagas disease. It develops in 20-30% 
of individuals and manifests as three major syndromes that may coexist in the same patient: 
arrhythmic, heart failure, and thromboembolism (systemic and pulmonary) (Rassi et al., 
1992, 2000). 
 
1.8. Diagnosis of Chagas disease: 
1.8.1. Acute phase: 
 
Several methods are available to search for parasites when they are present in large 
numbers. They could be divided into direct tests and concentration methods. 
 
1.8.1.1. Direct method: 
 
The simplest and cheapest direct test is the fresh blood smear. A drop of peripheral 
blood from the patient is collected from the ear, fingertip, foot, or from a vein through a 
syringe. Ten μL of blood is immediately deposited on a smear and a cover slip (22×22 mm) 
covers the drop. The amount of 10 μL is ideal for a preparation (i.e., a very thin smear that 
allows seeing red blood cells separated from each other). The preparation should be 
mounted in a microscope with an objective of 40× and ocular of 10× (i.e., 400×). If T. cruzi 
is present, it will be seen as a refringent body with very quick movements, disturbing the 
quiet red blood cells (Brener, 1984). 
 
1.8.1.2. Concentration method: 
 
The Strout technique is very simple. Blood (3-5 mL) is collected without 
anticoagulant and left to clot, at room temperature, once the clot is formed (15-60 min) the 
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blood exudate is transferred with a pipette to a centrifugal tube and spun down at low speed 
(i.e., 50 g, 500 rpm according to the radius of the centrifuge) for 5 min. This will allow the 
separation of most of red blood cells. Take all the supernatant and transfer to another 
centrifuge tube and spin hard (i.e., 500 g, around 2000 rpm) for 10 min. This will clear the 
suspension, having a clear supernatant. Supernatants are taken and stored for serology tests. 
The last drop remaining at the bottom of the tube is resuspend and a sample of 10 μL is 
taken on glass slide and cover slip, with the same methodology as the fresh blood smear 
(Strout, 1962). 
 
1.8.1.3. Microhematocrit method: 
 
Microhematocrit is very useful for congenital infection, because of the need of low 
sample quantity needed (100 μL of blood for each test). Collected from the plantar region 
of the baby’s foot, using heparinised glass capillaries Samples are centrifugated and 
analyzed under microscope for T. cruzi parasites. Microhematocrit method has 95% 
sensitivity (Freilij et al., 1983). 
 
1.8.2. Chronic phase: 
 
1.8.2.1. Xenodiagnosis: 
 
This method was firstly applied by Brumpt in 1914, a method of diagnosing a 
vector-transmitted infection (i.e., Chagas' disease), in which a laboratory-reared, pathogen-
free triatomine bug is allowed to suck blood from a patient. The intestinal contents of the 
insect are then examined for the presence of T. cruzi. The advantages of this technique are 
that it may be performed in the field (it is only necessary to transport bugs with 15 days on 
fast), does not require sterile handling, and allows for inoculation in animals and humans 
(Santos et al., 1995; Franco et al., 2002). 
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1.8.2.2. Hemoculture: 
 
This method depends on the culture of venous blood in LIT-blood/agar medium, 
the parasite amastigotes growth is analyzed at 20, 30, and 45 days after inculcation (Chiari 
et al., 1989).  
 
1.8.3. Serological Tests: 
 
1.8.3.1. Indirect Hemagglutination Test (IHA): 
 
This method has several advantages which hold up to now, such as few steps low 
cost, no equipment, and quick results (1-2 h). The method mainly depends on the specific-
antigen adherence on the red blood globules superficies followed by the agglutination 
resulted from the reaction between homologous antigen and antibody which exists in the 
inactivated serum sample (Neal and Miles, 1970; Stavitsky and Jarchow, 1954). 
 
1.8.3.2. Indirect Immunofluorescence:  
 
Indirect immunofluorescence is used mainly in research laboratories or diagnostic 
centers. One of the advantages is that the same conjugate (antihuman IgG) may be used for 
the diagnosis of several diseases and the ability to use the same equipment (fluorescence 
microscope). This test is conducted by reacting serum with smear fixed epimastigotes and, 
after washing, incubating with conjugate. The smears are read in the fluorescence 
microscope. The key advantage of this test is very high sensitivity. It is quite hard to find a 
serum from an infected individual which does not react. However, a disadvantage is that 
this same extreme sensitivity may lead to cross-reactions with several diseases (Luquetti et 
al., 2008; Souza and Amato, 2012). 
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1.8.3.3. Enzyme Linked Immunosorbent Assay ELISA: 
 
In general terms the mechanism of this assay can be explained as antigens from the 
sample are attached to a surface. Then, a further specific antibody is applied over the 
surface so it can bind to the antigen. This antibody is linked to an enzyme, and, in the final 
step, a substance containing the enzyme's substrate is added. The subsequent reaction 
produces a detectable signal, most commonly a color change in the substrate. Results are 
accepted to be positive when the optical density is at least 10% higher than the cutoff (a 
curve with negative, low-positive, and high-positive controls) (Voller et al., 1975). 
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2. SPECIFIC BACKGROUND 
 
2.1. Vaccines: 
Vaccines have an indisputable impact on the control of many important human and 
veterinary diseases and unquestionably have shaped the health landscape of recent 
generations. The advantages of a Chagas disease vaccine would be significant not just in 
terms of public health but also economic and social development (Hotez and Ferris, 2006). 
Recently, the increasing knowledge about the immune response associated with Chagas 
disease has been valuable for the design and testing of vaccination approaches, the 
development of recombinant techniques allowed the production of different immunogens 
ranging from recombinant proteins to DNA and adenovirus vaccines for experimental T. 
cruzi infection (Garg and Bhatia, 2005; Cazorla et al., 2009). Recombinant proteins 
allowed testing several well defined antigens, but the main immune feature induced by 
these antigens is the production of specific antibodies. Unfortunately, antibodies are not as 
effective in controlling T. cruzi infection as they are in other infections. Parasites can 
persist as amastigotes inside host cells, avoiding direct contact with antibodies. Even after 
release from infected cells, parasites can survive and be readily detected in the bloodstream 
of chronically infected animals and patients despite the high level of specific antibodies 
circulating. Vaccination protocols have been successful at decreasing parasitemia, tissue 
damage, and mortality in mouse models immunized with different T. cruzi genes 
(Rodrigues et al., 2009). The main idea for vaccine production was divided in two 
concepts, the first concept is to produce vaccines against trypomastigotes to block their 
entry after a bite of an infected triatomine, and this will prevent the initiation or persistence 
of infection and limit the parasitemia. The second concept is to produce vaccines against 
intracellular replicative amastigotes would inhibit the propagation of parasites in a host and 
prevent the parasite from entering the blood. 
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2.1.1. Vaccine developmental forms: 
 
The earlier vaccine generation against T. cruzi was heat killed or subcellular 
fraction of the parasite, mainly defined in the usage of suboptimal contents of immunogenic 
proteins of epimastigotes (the divisible stage inside the vector's digestive system), and other 
infective and intracellular stages of T. cruzi. The vaccine was tested in different animal 
models (i.e., mice, dogs, guinea pigs and monkeys). A loss of protective epitopes during 
inactivation and fractionation, was believed to be the cause for the limited success met in 
those attempts (Bhatia and Garg, 2005; Bhatia et al., 2009). 
The next vaccine generation was testing live vaccines having constituents of T. 
cruzi strains accompanied by pharmacological agents treatments, serial passage in vitro 
cultures or genetic knockouts with a loss of potentially virulent genes (Bhatia and Garg, 
2005; Bhatia et al., 2009). These vaccines found to be effective in controlling the infection 
with a disadvantage the danger of reversion of the attenuated strains to a virulent form and 
the likelihood of increased virulence  
Antigens offered a number of attractive properties as vaccine candidates including 
those abundantly expressed in the infective and intracellular stages of T. cruzi and highly 
immunogenic in natural infection. Purified recombinant T. cruzi proteins were the lately 
next vaccine candidates’ generation, the usage of GP90, GP82, GP56, Cruzipain (Cz), 
paraflagellar rod (PFRs), TC52, complement-regulatory protein (CRP) and ASP2-purified 
recombinant proteins showed a significant suitability for inducing antibody responses, but 
they were not efficient in eliciting the cell-mediated immunity that is essential for 
controlling the pathogen intracellular stage. 
In the last two decades naked DNA vaccines were widely used for controlling T. 
cruzi infection, various plasmid or viral vectors which contain the gene of interest were 
directly injected to the tested animal, the usage of plasmids facilitate the expression of the 
recombinant gene inserted directly in the mammals host cells, which followed by the rapid 
host immune response. Various T. cruzi proteins were used as a DNA vaccine (i.e., TSA1, 
ASP1, ASP2, LYT1, CRP and Cz) Garg and Tarleton (2002). Some of those had a higher 
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protective immune response in mice models and other was capable of reducing the blocking 
or decreasing the inflammatory reaction in mice heart tissue and skeletal muscles 
(Vazquez-Chagoyan et al., 2011). 
Recent studies aimed to the importance of adjuvants in enhancing the vaccine 
efficacy, the usage of adjuvants firstly proposed and applied by (Menezes, 1965), and 
recently the examination of the cytokines had come to a great expectations cytokines like 
Interleukin (IL-12), co-stimulatory molecules (e.g. GM-CSF, CD40, HSP70) were used to 
enhance the Th1 immune response to a defined antigen vaccine, Granulocyte Macrophage 
Cell Stimulating Factor (GM-CSF) was chosen as a genetic adjuvant because it is a potent 
cytokine capable of enhancing the antigen-presentation capability of antigen presenting 
cells, such as dendritic cells. In addition, it facilitates B- and T-cell-mediated immunity 
(Warren and Weiner, 2000). IL-12 is a key cytokine involved in CD8+ T-cell activation and 
proliferation and in directing the immune responses to type 1 (Pan et al., 1999).  
Genome-based vaccines were considered to be the main focus of our study by 
using the sequence database of T. cruzi (El-Sayed et al., 2005). Sophisticated bio-
informatics programs are designed to evaluate gene functions on the basis of homologies to 
genes characterized in other organisms and the presence of motifs predictive of targeting, 
cellular localization, surface expression and functional characteristics of the gene product. 
Such programs, allowed to directly proceed from sequence information to antigenic target 
identification and vaccine design (Bhatia et al., 2004) have employed web based 
bioinformatics tool coupled with an experimental strategy to Vaccine Development Against 
Trypanosoma cruzi identify the putative genes encoding glycosyl-phosphatidylinositol-
anchored (GPI anchor) or secreted proteins in a T. cruzi-expressed sequence tag database. 
Molecular and biochemical characterization of eight of the sequences selected by this 
approach identified three candidates (e.g. TcG1, TcG2 and TcG4) that were conserved in 
the genome of T. cruzi strains of clinical importance. These were expressed in different 
developmental stages of the parasite and immunogenic in multiple hosts. The selected 
candidates were recognized by lytic antibodies and CD8+ T cells in infected mice (Bhatia 
and Garg, 2008). Mice immunized with the selected antigens presented with a trypanolytic 
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antibody response that was in agreement with the intensity of the surface expression of 
these proteins in infective and intracellular stages of the parasite (Bhatia et al., 2004) and 
the type 1 cytokine (IFN-γ > IL4) profile. Since then, the protective efficacy of TcG1, 
TcG2 and TcG4 (individually or in combination with and without IL-12 and GM-CSF 
cytokine adjuvants) in mice have been examined. Data clearly established that co-delivery 
of the antigens elicited additive immunity and protection from T. cruzi infection, Upon 
challenge infection, TcVac2-vaccinated mice expanded the antigen-specific IgG2b/IgG1 
antibodies (TcG4 > TcG2 > TcG1) and elicited a CD8+-dominant T-cell response 
(CD8/CD4 ratio > 3) associated with type 1 cytokines (IFN- γ and TNF-α) when compared 
to controls that elicited a mixed type 1/type 2 cytokine response against T. cruzi infection. 
Importantly, with control of parasite burden, the splenic activation of CD8+ T cells and 
IFN- γ/TNF- α cytokines that are of pathological importance in chronic disease subsided 
and IL-4/IL-10 cytokines became dominant in vaccinated mice. Accordingly for the first 
time, a vaccine showed a successful efficacy in reducing the tissue parasite burden by first 
priming a polarized type 1 T-cell response and then switching to a type 2 dominance 
suppressing the evolution of immunopathology and tissue damage that are an outcome of 
consistent immune activation in chronic Chagasic disease. 
 
2.2. Mice model: 
Mice have been more frequently used as experimental models to study Chagas 
disease for several reasons. They are easily reproduced, of low cost, easy to handle, easy to 
be experimentally infected, and maintained in experimental conditions. Different strains of 
mice present distinct patterns of susceptibility to T. cruzi infection, chosen according to the 
virulence of the parasite strain or the objective of the study. Moreover, nowadays the 
existence of several knockout lineages has facilitated the study of different immunological 
aspects of T. cruzi infection. 
The acute phase is easily reproduced in this model (Collier et al., 1942; Federici et 
al., 1964) making this species very useful to isolate. Young mice are very susceptible to 
infection, and parasite strain, inoculum, and route of inoculation influence the development 
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of the infection. Different aspects of acute disease have been reproduced in mice, including 
symptoms (anorexia, elevated temperature, weight loss, decrease of general activity, patent 
parasitemia, general edema, and mortality) and histopathological lesions (diffuse 
myocarditis, myositis, lymphadenopathy, and congestion with infiltrate of mononuclear 
cells). The humoral immune response of mice was studied by Peralta et al., 1980, Jeng and 
Kierszembaum (1984), which changed in relation to different parasite and host strains. 
IgM, IgG, and isotypes IgG1, IgG2a, IgG2b, and IgG3 were observed, with the IgG2a more 
associated with protection (Andrade et al., 1985). Later, it was discovered that IgG1 and 
IgG2 are the most important IgG isotypes with participation on the phenomenon of lyses 
mediated by complement, the most important humoral process of protection in chronic 
chagasic infection (Krettli et al., 1984). Several pathological phenomena of T. cruzi 
infection were first studied in murine models, such as cellular damage, inflammation, 
fibrosis and denervation, which explain the disease evolution and characterize the different 
clinical forms of the disease. 
One of the principal limitations of mouse model is the short life span of this 
species (approximately 2 years) which probably makes impossible the reproduction of the 
later clinical forms of the disease, such as intense fibrosis, dilated myocardiopathy, 
aneurysm, and the digestive clinical forms, specially megaesophagus and megacolon, all of 
later evolution. However, the recent advances obtained in the study of several aspects of 
Chagas disease immunology in this animal, as well as the use of murine model for test of 
new drugs, together with ease of use, fully justify the use of this model. 
 
2.3. Electroporation system: 
Different non-viral approaches have been proposed for drug and gene delivery 
such as physical and chemical methods. Physical delivery systems are one of the efficient 
non-viral methods including electroporation, micro-injection, gene gun, tattooing, laser and 
ultrasound (Bolhassani and Rafati, 2011). Electroporation (EP) is the formation of aqueous 
pores in lipid bilayers by the application of a short (microseconds to milliseconds) high-
voltage pulse to overcome the barrier of the cell membrane. This transient, permeabilized 
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state can be used to load cells with a variety of different molecules including ions, drugs, 
dyes, tracers, antibodies, oligonucleotides, RNA and DNA (Faurie et al., 2005). 
Electroporation has proven useful both in vitro. In addition, the data show that 
electroporation of DNA vaccines in vivo is an effective method to increase cellular uptake 
of DNA and gene expression in tissue leading to marked improvement in immune 
responses. Electroporation represents a way of increasing the number of DNA-transfected 
cells and enhancing the magnitude of gene expression, while reducing intersubject 
variability and requiring less time to reach a maximal immune response compared to 
conventional intramuscular injection of the vaccine (Monie et al., 2010). Delivery of DNA 
vaccines using electroporation has already been tested successfully in a wide range of 
disease models. Electroporation has been used to enhance immune responses using DNA 
vaccines directed against infectious diseases such as influenza, HIV, hepatitis C, malaria, 
anthrax or to treat or prevent the development of tumors including breast cancer, prostate 
cancer and melanoma (Daemi et al., 2012; Best et al., 2009). 
The application of in vivo electroporation to the sites receiving injected plasmid DNA has 
allowed for dramatic increases in immune responses compared with plasmid DNA injection 
alone (Widera et al., 2000). Regarding to in vivo EP is predominantly carried out 
intramuscularly, currently, skin EP is used as an attractive and less invasive option that is 
able to induce robust adaptive immune responses. To date, studies of DNA EP in skin have 
mainly focused on antigen expression, antigen specific humoral immunity, induction of 
IFN-γ producing T cells and protective efficacy to infection (Daemi et al., 2012; Brave et 
al., 2011). Plasmid DNA vaccination using skin electroporation (EP) is a promising method 
able to elicit robust humoral and CD8+Tcell immune responses while limiting invasiveness 
of delivery (Brave et al., 2011). The investigators have shown that low-voltage 
electroporation can induce immunity and protect mice effectively (Daemi et al., 2012; Zhou 
et al., 2008). In addition, intradermal DNA electroporation is one of the most efficient non-
viral methods for the delivery of gene into the skin (Lin et al., 2012). 
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3. JUSTIFICATION 
 
Chagas disease (CD) is one of the most important Neglected Tropical Disease 
(NTD) in Latin America, this disease also known as the "forgotten" which affects most 
vulnerable population who has limited public voice. NTDs have an enormous impact on 
individuals, families in low income countries. CD is endemic in Latin America, but due to 
the large population mobility, CD has reached many countries (i.e. Japan, Canada; USA, 
Europe, Australia), CD causes around 10,000 death each year ad it was estimated that 10 
million people are infected, and around 75-90 million are at risk of being infected, CD is a 
global health problem so that the world Bank have classified CD as it is more prevalent 
than Malaria or Dengue and states that each year 725,000 workdays are lost due to 
premature deaths, the loss of 1,200 million USD within the seven countries of the southern 
cone and 5.6 million USD are lost in Brazil due to the absence of workers.  
CD has only two treatments of limited access until now (Nifurtimox and 
Benznidadzol) moreover, they are not perfect because: They are not effective in the chronic 
phase of the disease, cannot be used for children of age under 10 years old and finally it 
may cause serious adverse side effects. The vaccine research institutions have not been able 
to develop a new vaccine with 100% sterile immunity. The budget of NTD organization 
only give less than 1% for the research of CD, just 20 million out of the 3.063 million USD 
are spent on Chagas research. More research and development are needed to secure the 
families who suffer the infection with CD. 
With our work in investigating new techniques and ways in improving and 
enhancing the immune responses to the actual developed vaccines, we are so close to 
produce a long lasting, low cost and effective vaccine to treat CD, so more investigation is 
needed to solve the endemic Chagas disease problem.  
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4. HYPOTHESIS 
 
Electroporated TcVac1-vaccinated BALB/c mice induce higher protective immune 
response against T. cruzi infection with trypomastigotes Sylvio10x/4 strain more than 
intramuscularly vaccinated mice. 
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5. OBJECTIVES  
 
Evaluation of the recombinant DNA vaccine efficiency (TcVac1) using the 
electroporation system, measuring the immune response in electroporated and 
intramusculary vaccinated BALB/c mice with T. cruzi Sylvio 10X/4 strain infection. 
 
1. Specific objectives: 
1. Recombinant DNA vaccine, cloning and production. 
2. Evaluate the vaccine immune response of the mice before challenging. 
3. Production of T. cruzi (Sylvio 10X/4) strain in vitro and prepare it for mice 
challenging. 
4. Infecting the vaccinated mice with T. cruzi (Sylvio 10X/4).  
5. Clinical evaluation for the mice during the experiment. 
6. Evaluate the vaccine immune response of the mice after challenging. 
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6. MATERIAL AND METHODS  
 
The presented work was done in the molecular biology laboratories of CIESA 
(Centro de Investigaciones y Estudios Avanzados en Salud Animal) of the FMVZ-UAEM 
(Facultad de Medicina Veterinaria y Zootecnia-perteneciente a la-Universidad Autónoma 
del Estado de México).  
 
6.1. General strategy 
In our investigation 72 BALB/c mice were separated into 12 mice groups (n=6) on 
two phases according to the following diagram:  
a. Phase one (pre-infection): 
Table 1: Experimental groups: Vaccination before Challenge infection with T. cruzi.  
Technique Group Mice No. 
Electroporation 1-TcVac 6 
 2-pcDNA3.1 6 
 3-No DNA 6 
Intramuscular 4-TcVAC 6 
 5-pcDNA3.1 6 
 6-No DNA 6 
TcVac1; PcDNA3.1.TcG2, PcDNA3.1.TcG4, PcDNA3.MSP35, PcDNA3.MSP45, PcDNA3.GMCSF; 
Positive Control, pcDNA3.1; No DNA, Saline solution. 
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b. Phase two (post-infection): 
Table 2: Experimental groups: Vaccination after Challenge infection with T. cruzi. 
Technique Group Mice No. 
Electroporation 7-TcVac 6 
 8-pcDNA3.1   6 
 9-No DNA 6 
Intramuscular 10-TcVac 6 
 11-pcDNA3.1   6 
 12-No DNA 6 
TcVac1; PcDNA3.1.TcG2, PcDNA3.1.TcG4, PcDNA3.MSP35, PcDNA3.MSP45, PcDNA3.GMCSF; 
Positive Control, pcDNA3.1; No DNA, Saline solution. 
 
6.2. Immunization: 
All the mice groups were vaccinated with antigen encoding plasmids (PcDNA3-
TcG2, PcDNA3-TcG4) 25µg of each plasmid/mouse and cytokines encoding plasmids (IL-
12) (PcDNA3-msp-35, PcDNA3-msp-40) and (PcMVI-GMCSF, 25µg of each 
plasmid/mouse) where GMCSF (granulocyte macrophage stimulating factor), one total 
dose of 125µg DNA in 4 applications with 15 days difference between each application 
(Shivali Gupta and Nisha Jain Garg, 2010). All the antigen encoding plasmid and cytokines 
encoding plasmid were constructed donated by Dr. Nisha Garg, UTMB, Texas, USA. 
Two weeks after the last immunization, mice were challenged with T. cruzi 
trypomastigotes (Sylvio 10X/4 strain), 10,000 parasites/mouse were intraperitoneally 
injected with 30μl total volume. 
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Sixty days post-infection mice were sacrificed which correspond to the acute phase 
of the infection. Blood sample drops were taken every other day from each mouse to 
evaluate parasite count (parasitemia) using the "Fresh tail blood drop analysis", blood was 
collected before mice sacrifice for serological analysis using ELISA technique.  
6.3. Animals  
Female BALB/c homozygous mice with age between 6-9 weeks, the mice were 
obtained from the animal facility of CINVESTAV-IPN (Centro de Investigación y de 
Estudios Avanzados del Instituto Politécnico Nacional, México). Mice were kept during the 
experiment in CIESA (Centro de Investigacion y Estudios Avanzados en Salud Animal). 
All experimental protocols were conducted under the technical specifications for the 
production, care and use of laboratory animals from the Norma Official Mexicana (NOM-
62-ZOO-1999), and the council for international Organizations of Medical Science. Mice 
were euthanized according to the Norma Oficial Mexicana (NOM-033-Z00-1995). All 
protocols were approved by the Laboratory Animal Care Committee at the Facultad de 
Medicina Veterinaria y Zootecnia of the Universidad Autónoma del Estado de México 
(UAEM). 
 
6.4. Parasites  
T. Cruzi trypomastigotes (Sylvio 10X/4) strain was cultivated in continuous 
monolayer phases of C2C12 cell line, in DMEM medium with 10% fetal bovine serum 
(HyClone, USA), PH 6.8, at 37 ºc, 5% CO2 and 85% humidity (Chagoyan et al., 2011). 
 
6.5. Vaccination  
Mice groups were immunized intramuscularly and intradermally then 
electroporated in only intradermally injected mice groups with 5 pulses at 450 volts, 0.050 
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msec pulse interval and 0.125 msec band width. In both, antigen encoding plasmids and 
cytokines encoding plasmids were injected with (25µg of each plasmid/mouse) in total 
volume of 40µl and 30µl for intramuscularly and intradermally vaccination respectively. 
The plasmids obtained from Dr. Nisha were produced and cloned by transformation 
protocol in calcium chloride E. coli (DH5α) competent cells, and were cultivated on LB-
Broth plates with 100µg/ml ampicillin (MAX Efficiency® DH5α™ Competent Cells, Cat. 
No. 18258-012, Invitrogen). Then plasmids were extracted and purified using GeneJET 
Plasmid Maxiprep Kit (Cat. K0492). The DNA vaccine was prepared as a cocktail of all 
plasmids and administered as mentioned above.  
 
6.6. Serology  
The mice blood were collected from the eye cavity during the experiment or 
directly from the heart at the time of sacrifice, the blood samples were kept to clot at 4ºc 
and serum was separated, all serum samples were kept in Eppendorff tubes at -20ºc for 
analysis. 
 
6.6.1. Lymphocyte proliferation analysis  
 
Lymphocyte proliferation assay was used to determine lymphocyte activation and 
the cell-mediated immune responses. When B cells encounter their specific antigens, with 
the help of T cells, B cells are stimulated to undergo proliferation. When T cells are 
activated by antigen-presenting cells and cytokines, T cells undergo proliferation. The 
proliferation of B and T cells leads to clonal expansion and the initiation of the specific 
immune responses, indicating that the immune system has been primed with specific 
antigens. 
Mice were sacrificed and spleens were dissected out and washed in chilled PBS. 
With the help of sterile forceps, spleen tissue was teased and then mashed in 40 µm Nylon 
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Cell Strainer, then washed with 3ml of PBS. Cell suspension was collected and gently 
added to Histopaque®-1077 sterile-filtered, density: 1.077 g/mL (Sigma), then centrifuged 
at 2300 rpm for 30 min. at room temperature. Splenocytes were gently isolated and washed 
twice with PBS. Supernatants were discarded and pellet was resuspended with RPMI-1640 
medium (Product. No. R0883, Sigma) complemented with 10% Fetal Bovine Serum (FBS). 
Splenocytes were stained with Trypan blue and counted by hemocytometer. The 96 plates 
were prepared with antigens which correspond to the vaccine (TcG2, TcG4 proteins 
10μg/ml). Reagent grade Phytohaemaglutinin (PHA, Thermo Scientific Remel™) was used 
to stimulate mitotic division of lymphocytes maintained in cell culture as positive control, 
and splenocytes with RMPI-10%FBS were used as negative control. MTS (CellTiter 96® 
AQueous One Solution Cell Proliferation Assay, Sigma) was used as a colorimetric method 
for determining the number of viable cells in splenocytes proliferation assay. Optical 
density was read at 495 nm using EPOCH microplate reader. 
 
6.6.2. Specific antibody response through ELISA technique 
 
Serum samples were collected and preserved at -20ºc, then analyzed for IgG and 
IgG subtypes (IgG1, IgG2a, IgG2b) levels using an Enzyme Linked Immunosorbent Assay. 
Nunc Maxisorp (96 well) plates were coated with NaCO3/NaHCO3 PH 6.8 coating buffer 
containing T. cruzi antigens (TcG2, TcG4, 5μg/ml protein each) 200μl/well then incubated 
sequentially over night at 4ºc. Then plates were washed twice with 200μl PBS 1X-0.05% 
solution, then blocked with 5% NFDM/PBS (non fat dry milk) and incubated for 60 min. at 
37ºc.Plates were incubated for 2 hrs with test sera diluted to 1:100 with PBS-
0.05%/NFDM, 100μl/well then washed 6 times as mentioned. Plates were incubated at 
room temperature for 30 min with 100μl of biotin-conjugated goat anti-mouse IgG and IgG 
subtypes IgG1, IgG2a, IgG2b (1:2000 dilution in PBST-0.5% NFDM), color were 
developed with 100 μl/well sure blue TMB substrate (3,3´5,5´-tetramethyl benzidine) and 
the reaction was stopped with100 μl/well 5N sulfuric acid. Optical density was measured at 
450 nm using EPOCH microplate reader (Garg et al., 2010).  
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6.7. Parasitemia 
Parasitemia was determined by fresh blood smear test every other day starting 2 
weeks post infection during the experiment for each mouse until no parasites were detected. 
Samples were analyzed under 400x magnification power simple microscope, and parasites 
were counted in all sample fields. 
6.8. Statistical analysis 
Data are expressed as means with SEM (standard error of the mean), and derived 
from at least triplicate observations per sample (n=6 animals/group). Results were analyzed 
for significant differences using one way analysis of variance ANOVA procedures, 
Bartlett's test for equal variance and Tukey's multiple comparison tests. The level of 
significance was calculated vector only-versus-immunized TcVac1 and IDE versus IM 
immunization with. Differences were considered significant at p˂0.05, p˂0.001, p˂0.0001 
levels. 
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7. RESULTS 
7.1. Lymphocyte proliferation levels for intradermally electroporated and 
intramuscularly vaccinated mice groups. 
Some differences were found in lymphocyte proliferation between animals from 
different treatments before and after challenge. As expected, animals treated with saline 
solution and pcDNA3 had no proliferation neither when intramuscularly injected nor in 
animals intradermally injected and electroporated, with the exception of PHA stimulated 
splenocytes which proliferated in an equivalent manner to the splenocytes from all other 
groups (data not shown). When comparing TcVac1 treatments, splenocytes belonging to 
IDE animals, displayed higher proliferation values than splenocytes coming from IM 
vaccinated animals for TcG2 (0.417) or TcG4 (0.504) recombinant proteins (Fig 4A), but 
they did not proliferated when exposed to pcDNA3 or saline solution (data not shown). 
After challenge infection (60 dpi) splenocytes proliferation, was evident for all infected 
animals when exposed to PHA, TcG2 or TcG4 recombinant proteins, but they did not 
proliferated when exposed to pcDNA3 or saline solution (data not shown). Splenocytes 
from animals from IDE/TcVac1 group showed higher splenocyte proliferation, than 
splenocytes from IM/TcVac1 and control groups when exposed to TcG2 (1.109) or TcG4 
(1.279) recombinant proteins (Fig. 4B). 
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Figure 4: TcG2 and TcG4 recombinant proteins elicit a stronger in-vitro proliferation 
in splenocytes from TcVac1/IDE than from TcVac1/IM immunized animals before 
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and after challenge infection. (A) IDE mice groups’ showed higher significant differences 
of splenocytes response corresponding to TcG2 and TcG4 antigen encoding plasmids with 
p˂0.001 and p˂0.0001 versus control and p˂0.05 and p˂0.001 levels versus IM, while 
intramuscular mice groups showed a lower significant difference with p˂0.05 levels for 
both TcG2 and TcG4 antigen encoding plasmids versus control. (B) IDE mice groups 
showed a significant high level for TcG2 and Tcg4 antigen encoding plasmids with 
p˂0.0001 for both versus control and p˂0.001 versus both antigen encoding plasmids 
versus IM mice groups. Finally, IM mice groups shoed a lower significant level for both 
antigen encoding plasmids with p˂0.001 levels versus control. Splenocytes proliferations 
analysis was monitored at 495 nm using EPOCH microplate reader. 
 
7.2. Immunoglobulin G (IgG), IgG subtypes (IgG1, IgG2a,IgG2b) and 
Immunoglobulin M levels in all mice groups determined by ELISA Assay.  
Immunoglobulin G (IgG) and IgG subtypes (IgG1, IgG2a, IgG2b) levels in all 
treatment groups were assessed to evaluate the immune response for the vaccine before 
animals were experimentally infected with T. cruzi trypomastigotes. Serum samples were 
analyzed 15 days after the last immunization and substantial levels of recombinant protein-
specific antibodies IgG˃IgG2a˃IgG2b˃IgG1 in mice immunized with TcG4- and TcG2-
encoding plasmids for both IDE and IM vaccinated groups were detected. It was found that 
animals from IDE/TcVac1 group had larger surges of all IgG’s studied than animals from 
the IM/TcVac1 group (Fig 5A, 5B, 5C). After challenge, IgG levels from all subtypes 
increased significantly in all TcVac1 vaccinated animals; however IgG increments were 
significantly larger for IDE/TcVac1 vaccinated animals than for IM/TcVac1 vaccinated 
animals (Fig 6A, 6B, 6C). 
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Figure 5: rTcG2 and rTcG4 proteins elicit stronger IgG antibody levels in mice with 
intradermal electroporation than with Intramuscular injection with TcVac1, before 
challenge infection. Mice were immunized with 4 vaccine boosts, 15 days after the last 
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immunization mice sera were collected and analyzed by ELISA assay at (1:100) sera 
dilution. (A & B) Specific antibody responses were measured corresponding to 
immunoglobulin G and IgG subtypes (IgG1, IgG2a, IgG2b). A higher antibody response 
was observed in electroporated mice groups versus intramuscular mice groups (P˂0.001 
and p˂0.0001) in pre- and post-infection periods. IDE versus control showed a high 
antibody responses with (P˂0.001 and p˂0.0001) while, IM versus control did not showed 
a lower response but not statistically significantly different. (C) TcG2 and TcG4 antigen-
encoding plasmids Specific antibody response were measured for IgG, IgG2b and IgG1 
respectively for IDE mice groups versus IM mice groups showing a significant higher 
responses of all compared immunoglobulins for IDE mice more than IM groups (P˂0.001 
and p˂0.0001).  
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Figure 6: rTcG2 and rTcG4 proteins elicit stronger IgG antibody levels in mice with 
intradermal electroporation than with Intramuscular injection with TcVac1, after 
challenge infection. Mice were immunized with 4 vaccine boosts, 15 days after the last 
immunization mice were infected with T. cruzi trypomastigotes (Sylvio 10X/4) 
(10,000/mouse). 60 days post infection sera were collected and analyzed by ELISA assay at 
(1:100) sera dilution. (A & B) Specific antibody responses were measured corresponding to 
immunoglobulin G and IgG subtypes (IgG1, IgG2a, IgG2b). A higher antibody response 
was observed in IDE mice groups versus IM mice groups (P˂0.001 and p˂0.0001) in all 
IgG and IgG subtypes for TcG2 and TcG4 antigen-encoding plasmids. A significant higher 
response for IDE mice groups versus Control (P˂0.001 and p˂0.0001) and lower 
significant antibody responses (P˂0.05 and p˂0.001) for IM mice groups versus control in 
both TcG2 and TcG4 antigen-encoding plasmids. (C) TcG2 and TcG4 antigen-encoding 
plasmids Specific antibody response were measured for IgG, IgG2b and IgG1 respectively 
for IDE versus IM mice groups showing a significant higher responses of all compared 
immunoglobulins for IDE vaccinated mice (P˂0.001 and p˂0.0001). 
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Abstract  
Introduction: Trypanosoma cruzi, a parasitic protozoan, is the etiologic agent of Chagas 
disease. Chagas disease is one of the most common causes of congestive heart failure 
related deaths among young adults in the endemic areas of South and Central America and 
Mexico. It has also become an important health issue in the United States and Europe due 
to large scale migration of Latin Americans over the last few decades. No vaccines are 
currently available until now. In this study, we tested the vaccine efficacy of two antigen 
candidates against T. cruzi infection and disease in a mouse model. The use of TcVac1 
(TcG2, TcG4, T cruzi antigen encoding plasmids, interleukin-12 [IL-12] and granulocyte-
macrophage colony-stimulating factor [GMCSF] encoding plasmids as genetic adjuvants) 
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anti T. cruzi candidate vaccine injected intramuscularly has been previously reported in 
mice with encouraging results. Here we evaluated the comparative protection conferred by 
TcVac1 when administrated intramuscularly (IM) versus an intradermal/electroporation 
(IDE) vaccination protocol. Twelve BALB/c mice per group were vaccinated four times 
fifteen days apart. Six animals (n=6) from each treatment were sacrificed two weeks after 
the last immunization for pre-infection vaccine efficacy evaluation, after challenge with T. 
cruzi trypomastigotes (Sylvio X10/4 strain), the remaining animals (n=6) were sacrificed 
60 days post-infection (dpi). Immune response was assessed through anti-TcG2 and TcG4 
T. cruzi antigens. Specific serum antibodies with an Enzyme Linked Immunosorbent Assay 
(ELISA) and lymphocyte activation against the studied antigens was evaluated through a 
lymphocyte proliferation assay. 
Results: We found that IDE induced significantly larger surges of IgG antibodies including 
subtypes IgG1, IgG2a and IgG2b, during the pre- and post-infection periods for the two 
antigens used in the experiment. The ratio of antibodies IgG2b/IgG1 was >1 for TcG2 
antigen in the pre-infection period in both administration routes. However for the TcG4 
antigen the ratios were opposite for animals belonging to different administration routes<1 
for IDE and >1 for IM. During the post infection period for both treatments IgG2b/IgG1 
ration was always <1. These results suggest, as previously reported, that a switch from Th1 
to Th2 type immune response occurs in vaccinated/infected animals. Our splenocyte 
proliferation assays demonstrated that both antigens were able to induce splenocyte 
proliferation during the pre-infection period. However, we observed that animals from the 
IDE group induced more proliferation than IM mice group when TcG4 was used to activate 
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the cells, which was also observed during the post-infection phase of the experiment. We 
did not record any animal deaths during the infection however vaccinated mice appeared to 
have healthier status than the control animals. 
Conclusion: Electroporation technique enhances the TcVac1 vaccine uptake in the 
experimented mice skin tissue leading to high specific immune response in both pre- and 
post-infection periods compared to the intramuscular technique. 
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Introduction  
Trypanosoma cruzi is one of the most devastating parasite infection diseases in Latin 
America [5]. It is the etiologic agent of Chagas disease and it is mainly transmitted to 
humans by blood-sucking triatomine bugs. Chagas disease has two successive phases, acute 
and chronic. Once the acute phase abates, most of the infected patients recover an apparent 
healthy status in the form of the chronic infection. After several years of the chronic phase, 
20-35% of the infected individuals will develop irreversible lesions of the autonomous 
nervous system in the heart, esophagus, colon, and peripheral nervous system, outlasting 
the rest of the infected individual's life. Chagas disease represents the first cause of cardiac 
lesions in young, economically productive adults in the endemic countries of Latin America 
[1, 2, 3, 4]. It is an important health issue in most of the Latin American countries and due 
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to human migration; it has become an important health issue in the United States and 
Europe [5]. Vector control programs have not been able to completely prevent parasite 
transmission [6], the available anti-parasite drugs are not sufficiently safe or effective [7], 
and no vaccines are currently available. 
Vaccines have an indisputable impact on the control of many important human and 
veterinary diseases and unquestionably have shaped the health landscape of recent 
generations. The advantages of a Chagas disease vaccine would be significant, not just in 
terms of public health but also economic and social development [8]. Recently, the 
increasing knowledge about the immune response associated with Chagas disease has been 
valuable for the design and testing of vaccination approaches, the development of 
recombinant techniques allowed the production of different immunogens ranging from 
recombinant proteins to DNA and adenovirus vaccines for experimental T. cruzi infection 
[9, 10]. 
Many, T. cruzi derived proteins have been tested as potential vaccine antigens. 
Unfortunately, antibodies are not as effective in controlling T. cruzi infection as they are in 
other infections. In spite of vaccination protocols with different T. cruzi antigens most 
approaches have been only partially successful at decreasing parasitemia, tissue damage, 
and mortality in immunized mouse models [11]. The main idea for vaccine production is, 
on one hand to prevent the initiation or persistence of infection and limit the parasitemia, 
and on the other hand to fight intracellular replicative amastigotes. 
Several investigators have shown the potential utility of T. cruzi surface antigens as 
vaccine candidates in mice [12, 13]. Our group has performed computational screening of 
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T. cruzi sequence databases reported in GenBank, and identified genes encoding 
glycosylphosphatidylinositol (GPI)-anchored proteins TcG2 and TcG4 as potential vaccine 
candidates. These antigens were chosen after an unbiased computational/bioinformatics 
screening of the T. cruzi genome sequence database that led to the identification of 11 
potential candidates [14]. Through rigorous analysis over a period of several years, we 
determined that three candidates (TcG2, TcG4) were maximally relevant for vaccine 
development. These two candidates are phylogenetically conserved in clinically important 
T. cruzi strains, expressed in infective and intracellular stages of the parasite [15], and 
recognized by immunoglobulins and CD8+T cells in multiple T. cruzi-infected hosts [16]. 
When individually delivered as a DNA-prime/DNA-boost vaccine along with adjuvants 
(IL-12- and GM-CSF-encoding plasmids) in mice, these antigens elicited a significant 
trypanolytic antibody and Th1 cytokine (IFN-γ) response, a property that has been 
associated with immune control of T. cruzi [15]. Co-delivery of these antigens as DNA 
vaccine (TcVac1) induced additive immunity and higher degree of protection from T. cruzi 
infection than was observed with single vaccine candidates in mice [9]. Furthermore, these 
same antigens used as a DNA prime/MVA (modified virus Ankara; an attenuated vaccinia 
virus) based expression vector boost vaccine (TcVac3)elicited a type-1 effector T cell 
immunity that improved T. cruzi control during the acute phase of infection, and 
subsequently, predominance of anti-inflammatory responses prevented chronic 
inflammation and myocarditis in chagasic mice. Also DNA prime/protein boost vaccine 
(TcVac2) elicited an improved protection response over DNA prime/DNA boost (TcVac1) 
vaccine [17]. 
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Since antigen delivery protocol results in varying protection successes, we decided to 
test other DNA delivery systems. Physical delivery systems such as electroporation, 
microinjection, gene gun, tattooing, laser and ultrasound have been proven as efficient 
delivery methods [18]. Electroporation (EP) is the formation of aqueous pores in lipid 
bilayers by the application of a short (microseconds to milliseconds) high-voltage pulse to 
overcome the barrier of the cell membrane. This transient, permeabilized state can be used 
to load cells with a variety of different molecules including ions, drugs, dyes, tracers, 
antibodies, RNA and DNA [19]. Electroporation has proven useful both in-vitro and in-vivo 
protocols. In addition, the data show that electroporation of DNA vaccines in vivo is an 
effective method to increase cellular uptake of DNA and gene expression in tissue leading 
to marked improvement in immune responses. Electroporation represents a way of 
increasing the number of DNA-transfected cells and enhancing the magnitude of gene 
expression, while reducing intersubject variability and requiring less time to reach a 
maximal immune response compared to conventional intramuscular injection of the vaccine 
[20]. Delivery of DNA vaccines using electroporation has already been tested successfully 
in a wide range of infectious diseases such as influenza, HIV, hepatitis C, malaria, anthrax 
or to treat or prevent the development of tumors including breast cancer, prostate cancer 
and melanoma [21, 22].The application of in vivo electroporation to the sites receiving 
injected plasmid DNA has allowed for dramatic increments in immune responses compared 
with plasmid DNA injection alone [23].  
Regarding to in vivo EP is predominantly carried out intramuscularly, currently, skin 
EP is used as an attractive and less invasive option that is able to induce robust adaptive 
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immune responses. To date, studies of DNA EP in skin have mainly focused on antigen 
expression, antigen specific humoral immunity, induction of IFN-γ producing T cells and 
protective efficacy to infection [21, 24]. Plasmid DNA vaccination using skin 
electroporation (EP) is a promising method able to elicit robust humoral and CD8+Tcell 
immune responses while limiting invasiveness of delivery [24]. Researchers have shown 
that low-voltage electroporation can induce immunity and protect mice effectively [21, 25]. 
In addition, intradermal DNA electroporation is one of the most efficient non-viral methods 
for the delivery of gene into the skin [26]. 
Here we describe the protective efficacy of TcG2 and TcG4 vaccine candidates co-
delivered with genetic adjuvants (IL-12 and GM-CSF expression plasmids) through an 
intradermal electroporation approach. We discuss the function of vaccine-induced antibody 
and splenocyte responses against T. cruzi in providing protection from acute parasitemia in 
chagasic mice. 
Material and Methods  
Parasites 
T. Cruzi trypomastigotes (Sylvio 10X/4 strain) were cultivated in continuous monolayer 
phases of C2C12 cell line, in DMEM medium with 10% fetal bovine serum (HyClone, 
USA), PH 6.8, at 37 ºc, 5% CO2 and 85% humidity (Vázquez-chagoyán et al., 2011). 
Mice 
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BALB/c female mice (n=72, 6 to 8 week old) were obtained from CINVESTAV, IPN, 
Mexico, animal facility and divided into twelve treatment groups (n=6), according to table 
1. All experimental protocols were conducted under the technical specifications for the 
production, care and use of laboratory animals from the Norma Official Mexicana (NOM-
62-ZOO-1999) [29], and the council for international Organizations of Medical Science. 
Mice were euthanized according to the Norma Oficial Mexicana (NOM-033-Z00-1995) 
[30]. All protocols were approved by the Laboratory Animal Care Committee at the 
Facultad de Medicina Veterinaria y Zootecnia of the Universidad Autónoma del Estado de 
México (UAEM).  
TcVac1 vaccine preparation 
TcG2 and TcG4 cDNAs (SylvioX10/4 isolate, Genbank: AY727915 and AY727917, 
respectively) were cloned in eukaryotic expression plasmid pCDNA3.1 [31]. Plasmids 
encoding IL-12 (pcDNA3.msp35 and pcDNA3.msp40) and GM-CSF (pCMVI.GM-CSF) 
have been previously described [32]. Plasmids were transformed into E. coli (DH5- 
competent cells, grown in L-broth containing 100-mg/ml ampicillin, and purified using the 
GeneJET Plasmid Maxiprep Kit [33]. 
Table 1. Treatment groups 
a. Pre-infection phase: 
Table 1: 
b. Infection phase 
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Table 2:  
Immunization: 
Animals were treated either with DNA or placebo, either by intramuscular (IM) 
injection or by intradermal/electroporation (IDE). Intradermally injected mice were 
electroporated with 5 pulses at 450 volts, 0.050 msec pulse interval and 0.125 msec band width.  
Mice from the TcVac1 groups, IDE (n=6) and IM (n=6) were vaccinated with antigen 
and cytokine encoding plasmids (PcDNA3-TcG2, PcDNA3-TcG4; PcDNA3-msp-35, 
PcDNA3-msp-40 [IL-12] and pcMVI-GM-CSF), (25µg of each plasmid/mouse) in 4 doses 
with 15 days apart [27], or with pcDNA3.1 empty plasmid (n=6, 25μg) or saline solution 
(n=6) with the same frequency as animals receiving TcVac1. Two weeks after the last 
immunization animals were sacrificed for vaccine assessment through antibody response 
and lymphocyte proliferation assay. 
The remaining 6 groups of mice received the same treatments as the pre-infection 
groups, with the exception that animals received an intra-peritoneal challenge infection 
with (10,000 parasites/mouse) of T. cruzi trypomastigotes (Sylvio 10X/4 strain) in a 30μl 
total volume, two weeks after the last immunization. 
Sixty days post-infection, during the acute phase of the infection, mice were sacrificed 
and blood was collected for immunological evaluation. 
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Serology 
Mice blood was collected from the eye cavity during the experiment or directly from 
the heart at the time of sacrifice. Blood samples were kept to clot at 4ºc and serum was 
separated, all serum samples were stored at -20ºc until analyzed. 
 
Lymphocyte proliferation analysis  
Lymphocyte proliferation assay was used to determine lymphocyte activation and the 
cell-mediated immune responses. When B cells encounter their specific antigens, with the 
help of T cells, B cells are stimulated to undergo proliferation. When T cells are activated 
by antigen-presenting cells and cytokines, T cells undergo proliferation. The proliferation 
of B and T cells leads to clonal expansion and the initiation of the specific immune 
responses, indicating that the immune system has been primed with specific antigens. 
Mice were sacrificed and spleens were dissected out and washed in chilled PBS. With 
the help of sterile forceps, spleen tissue was teased and then mashed in 40 µm Nylon Cell 
Strainer, then washed with 3ml of PBS. Cell suspension was collected and gently added to 
Histopaque®-1077 sterile-filtered, density: 1.077 g/mL (Sigma), then centrifuged at 2300 
rpm for 30 min. at room temperature. Splenocytes were gently isolated and washed twice 
with PBS. Supernatants were discarded and pellet was resuspended with RPMI-1640 
medium (Product. No. R0883, Sigma) complemented with 10% Fetal Bovine Serum (FBS). 
Splenocytes were stained with Trypan blue and counted by hemocytometer. The 96 plates 
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were prepared with antigens which correspond to the vaccine (TcG2, TcG4 proteins 
10μg/ml). Reagent grade Phytohaemaglutinin (PHA, Thermo Scientific Remel™) was used 
to stimulate mitotic division of lymphocytes maintained in cell culture as positive control, 
and splenocytes with RMPI-10%FBS were used as negative control. MTS (CellTiter 96® 
AQueous One Solution Cell Proliferation Assay, Sigma) was used as a colorimetric method 
for determining the number of viable cells in splenocytes proliferation assay. Optical 
density was read at 495 nm using EPOCH microplate reader. 
 
Specific antibody response through ELISA technique 
Serum samples were collected and preserved at -20ºc, then analyzed for IgG and IgG 
subtypes (IgG1, IgG2a, IgG2b) levels using an Enzyme Linked Immunosorbent Assay. 
Nunc Maxisorp (96 well) plates were coated with NaCO3/NaHCO3 PH 6.8 coating buffer 
containing T. cruzi antigens (TcG2, TcG4, 5μg/ml protein each) 200μl/well then incubated 
sequentially over night at 4ºc. Then plates were washed twice with 200μl PBS 1X-0.05% 
solution, then blocked with 5% NFDM/PBS (non fat dry milk) and incubated for 60 min. at 
37ºc.Plates were incubated for 2 hrs with test sera diluted to 1:100 with PBS-
0.05%/NFDM, 100μl/well then washed 6 times as mentioned. Plates were incubated at 
room temperature for 30 min with 100μl of biotin-conjugated goat anti-mouse IgG and IgG 
subtypes IgG1, IgG2a, IgG2b (1:2000 dilution in PBST-0.5% NFDM), color were 
developed with 100 μl/well sure blue TMB substrate (3,3´5,5´-tetramethyl benzidine) and 
the reaction was stopped with100 μl/well 5N sulfuric acid. Optical density was measured at 
450 nm using EPOCH microplate reader. [27] 
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Parasitemia 
Parasitemia was determined by fresh blood smear test every other day starting 2 weeks 
post infection during the experiment for each mouse until no parasites were detected. 
Samples were analyzed under 400x magnification power simple microscope, and parasites 
were counted in all sample fields. 
8. Statistical analysis 
Data are expressed as means with SEM (standard error of the mean), and derived from at 
least triplicate observations per sample (n=6 animals/group). Results were analyzed for 
significant differences using one way analysis of variance ANOVA procedures, Bartlett's 
test for equal variance and Tukey's multiple comparison tests. The level of significance was 
calculated vector only-versus-immunized TcVac1 and IDE versus IM immunization with. 
Differences were considered significant at p˂0.05, p˂0.001, p˂0.0001 levels. 
 
Results 
Lymphocyte proliferation assay:  
Some differences were found in lymphocyte proliferation between animals from 
different treatments before and after challenge. As expected, animals treated with saline 
solution and pcDNA3 had no proliferation neither when intramuscularly injected nor in 
animals intradermally injected and electroporated, with the exception of PHA stimulated 
splenocytes which proliferated in an equivalent manner to the splenocytes from all other 
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groups (data not shown). When comparing TcVac1 treatments, splenocytes belonging to 
IDE animals, displayed higher proliferation values than splenocytes coming from IM 
vaccinated animals for TcG2 (0.417) or TcG4 (0.504) recombinant proteins (Fig 1A), but 
they did not proliferated when exposed to pcDNA3 or saline solution (data not shown). 
After challenge infection (60 dpi) splenocytes proliferation, was evident for all infected 
animals when exposed to PHA, TcG2 or TcG4 recombinant proteins, but they did not 
proliferated when exposed to pcDNA3 or saline solution (data not shown). Splenocytes 
from animals from IDE/TcVac1 group showed higher splenocyte proliferation, than 
splenocytes from IM/TcVac1 and control groups when exposed to TcG2 (1.109) or TcG4 
(1.279) recombinant proteins (Fig. 1B). 
Serological evaluation: 
Immunoglobulin G (IgG) and IgG subtypes (IgG1, IgG2a, IgG2b) levels in all 
treatment groups were assessed to evaluate the immune response for the vaccine before 
animals were experimentally infected with T. cruzi trypomastigotes. Serum samples were 
analyzed 15 days after the last immunization and substantial levels of recombinant protein-
specific antibodies IgG˃IgG2a˃IgG2b˃IgG1 in mice immunized with TcG4- and TcG2-
encoding plasmids for both IDE and IM vaccinated groups were detected. It was found that 
animals from IDE/TcVac1 group had larger surges of all IgG’s studied than animals from 
the IM/TcVac1 group (Fig 2A, 2B, 2C). After challenge, IgG levels from all subtypes 
increased significantly in all TcVac1 vaccinated animals; however IgG increments were 
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significantly larger for IDE/TcVac1 vaccinated animals than for IM/TcVac1 vaccinated 
animals (Fig 3A, 3B, 3C). 
 
Discussion  
DNA vaccination consists of the administration of a construct engineered to produce an 
antigen of interest designed to elicit immunity against pathogens or even cancer cells 
exposed to its action. Eventually, the encoded immunogen will be responsible for the 
generation of a pool of antigen-specific T cells, some of which will remain as memory cells 
for long term protection. This technology has been used for a wide range of applications, 
from laboratory tools to licensed veterinary vaccines [35]. Also relevant to the treatment of 
human disease, the increasing number of clinical trials predicts the tremendous therapeutic 
potential for this approach against cancer. Moreover, DNA vaccines present several 
advantages over other vaccination strategies, among which are the relatively higher stability 
of DNA that avoids cold chain disruption issues, as well as the low price and the ease in 
producing good manufacturing practices (GMP) by the use of vaccination grade DNA. [34, 
35] 
The effectiveness of T. cruzi genes as genetic vaccines for the elicitation of parasite-
specific immune responses has recently been shown in a number of laboratories with 
several different T. cruzi strains [9, 15, 16, 17, 27, 28, 31, 33, 36, 37, 38, 39, 40, 41, and 
42]. The antigenic potential of TcG2 and TcG4 was shown by studies of our group which 
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demonstrated that the encoded antigens elicited antibodies that bound to the parasite surface 
and exhibited trypanolytic and agglutination activities [16, 17]. 
Manipulation of antigen presentation and processing pathways is an important aspect in 
DNA vaccine technology. Several approaches have been studied in DNA vaccine designs, 
including: co-delivery of immune-modulatory molecules, diverse routes of administration 
or prime-boost regimens. Among the different DNA vaccine administration strategies 
reported, the use of naked plasmid DNA injected with intramuscularly (IM), the 
subcutaneously (SC), intradermally (ID) or intranasally approaches [43] and the epidermal 
transfection with either coated or naked DNA administered through gene gun [44]. Pros and 
cons have been reported for alternative vaccine strategies. For example: Viral mediated 
gene transfer by genetically modified viruses (lentiviruses, adenoviruses, adeno-associated 
viruses, and retroviruses) has high transfection efficiency and stability. However, 
disadvantages of these methods may be the production cost, putative toxic side effects, 
limited transgene size that can be used and the potential insertional mutagenesis that may 
be induced by these viral vectors, (reviewed by Fioretti et al [45]). Intramuscular or 
intradermal injection of plasmid predominantly leads to transfection of myocytes or 
keratinocytes. However, these type of cells lack expression of major histocompatibility 
complex (MHC) class II and for that reason they do not prime T lymphocytes directly. It is 
likely that immune priming occurs through dendritic cells (DCs) present at the site of DNA 
injection or that are attracted in response to inflammatory or chemotactic signals following 
vaccination. Dendritic cells are thought to be responsible for antigen presentation following 
direct transfection of plasmid DNA, (reviewed by Fioretti et al [45]). 
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TcG2 and TcG4 antigens have been tested experimentally in a series of combinations of 
TcVac anti-T. cruzi candidate antigens in order to test differential efficacies of the vaccine 
preparations. Vaccines strategies tested included pcDNA-prime/pcDNA-boost in mice and 
dogs (TcVac1) [17, 46], pcDNA-prime/recombinant protein boost (TcVac2) [17], and 
pcDNA-prime/MVA boost (TcVac3) [33]. 
TcVac1 vaccine elicited a strong Th1-type antibody response dominated by 
IgG2b/IgG1 isotypes, which were maintained after a challenge infection. Vaccinated 
animals controlled 50-90% of the acute phase tissue parasite burden. Lack of splenocyte 
proliferation of vaccinated/infected animals in vitro suggests that protection from challenge 
infection was not provided by an active T-cell response. TcVac2 vaccine also induced a 
strong IgG2b>IgG1 antibody response and a moderate level of lymphocyte proliferation in 
mice. After Challenge infection IgG2b>IgG1 antibody response expanded and elicited a 
substantial CD8+ T cell response, which is associated with type 1 cytokines (IFN-γ and 
TNF-α) that resulted in control of acute parasite burden. During chronic phase antibody 
response persisted, as well as CD8+ T cells, however IL-4/IL-10 cytokines became 
dominant in vaccinated mice. Tissue parasitism, inflammation and fibrosis in heart and 
skeletal muscle of TcVac2-vaccinated chronic mice were undetectable by histological 
techniques, as compared to non vaccinated/infected animals which exhibited persistent 
parasite burden and immunopathology in the myocardium. TcVac3 vaccine also elicited a 
strong IgG2b>IgG1 antibody response and a robust T. cruzi-specific CD8+ T cell response 
with Type-1 cytokine (IFN-γ + TNF-α> IL-4 + IL-10) and cytolytic effector phenotype. 
TcVac3 induced significantly effector T cells upon challenge infection and provided >92% 
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control of T. cruzi. In chronic phase of infection mice exhibited a significant decline (up to 
70%) in IFN-γ and CD8+ T cells a predominance of immune-regulatory IL-10/CD4+ T 
cell, and presented undetectable tissue parasitism, inflammatory infiltrate, and myocardium 
fibrosis. As a whole the experience with TcVac series vaccines suggests that a protective 
vaccine elicits a strong antibody response IgG2b>IgG1 and a robust T. cruzi-specific CD8+ 
T cell response with Type-1 cytokine (IFN-γ + TNF-α > IL-4 + IL-10) and cytolytic 
effector phenotype that even if it does not produce a sterile immunity, it does control 
parasitemia and tissue parasite burden. Then during the infection Th type 1 is switched for a 
Th type 2 immune response which is associated to a healing inflammation [27]. 
The TcVac vaccine series are designed for prime/boost doses. They all start with a 
DNA prime dose and finish with either, DNA, recombinant protein or viral vector boost. 
This difference may explain the dissimilarities found among treatments, and mainly with 
TcVac1.  
TcVac2 and TcVac3 induce a more effective immune response, however, production 
and purification of recombinant proteins or viral vectors is quite more expensive than 
plasmid DNA production and purification. Therefore we decided to test a more efficient 
way of administration of a DNA-prime/DNA-boost vaccine approach which we found in 
intradermal electroporation (IDE) vaccine administration, since it has been shown to be 
very effective in transfecting in-vivo cells with DNA vaccines and induce a high immune 
response.  
IDE promotes Th1 and Th2 type immune responses because on one hand it reversibly 
permeabilizes the target cells enhancing the uptake and expression of the gene of interest 
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[53, 54], and since the site of IDE contains many antigen-presenting cells (APCs), mainly 
dendritic cells, that can be directly transfected during the vaccination process, and therefore 
the expressed antigen is presented in association with major histocompatibility complex 
(MHC) class I molecules, which will subsequently stimulate the synthesis of a pool of 
antigen-specific cytotoxic T lymphocytes(CTL). Furthermore, epitope display mediated by 
MHC class 1 is prone to induce both a T helper type 1 (Th1) response in conjunction with 
the generation CTLs [47, 48], the most potent cytolytic effector cells. On the other hand, 
the tissue damage caused by the application of IDE causes inflammation and recruits 
antigen presenting cells (DCs, macrophages) and lymphocytes to the injection site inducing 
significant immune responses, including antibody production as well as T-cells. 
Furthermore, IDE can be repeatedly used in a prime/boost vaccine delivery strategy, since 
it does not induce undesirable immune responses against the delivery system (reviewed by 
Fioretti et al [45]). 
 
Here, we tested TcVac1 vaccine that includes pcDNA3.1-TcG2 and pcDNA3.1-TcG4 
mammalian cell expression plasmids, but, in order to maximize its protective capacity, we 
did not eliminate the adjuvant cytokine genes that can help enhance the response to the 
antigen-encoding plasmid(s). GM-CSF enhances the antigen-presenting capability of 
dendritic cells and facilitates B- and T-cell-mediated immunity [49, 50], and IL-12 enhance 
CD8+-T-cell activation and proliferation, and in promoting type 1 cytokine production [50, 
51, 52]. Co-administration of cytokine genes with T. cruzi antigen encoding plasmids have 
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been associated to an increment in the level of antigen-specific CTL activity and humoral 
immune responses and provided substantially better protection from T. Cruzi [27]. 
In this experiment we expected that the TcVac1 vaccine, delivered through IDE, should 
induce a stronger immune response than TcVac1 administered intramuscularly. We would 
expect an immune response more closely related to the responses found for TcVac2 and 
TcVac3 immunization protocols. 
We found that splenocytes coming from IDE /vaccinated animals proliferated more 
than the splenocytes derived from IM/vaccinated animals. O.D. (optical density) readings 
for TcG2 or TcG4 recombinant protein stimulated splenocytes were 0.42, 0.50 for TcG2 
and 0.38, 0.39 for TcG4 from IDE and IM vaccinated animals, respectively. During the 
acute phase of infection (60 dpi) the splenocytes proliferated even further for all vaccinated 
groups, while the differences kept favoring splenocytes coming from IDE vaccinated mice 
with O.D. values of 1.2, 1.25 for TcG2 and 0.75, 0.08 for TcG4 from IDE and IM 
vaccinated animals, respectively. This study demonstrates that animals vaccinated with 
TcVac1 by IDE develop stronger cell immunity than animals vaccinated with IM vaccine 
administration. These results are not surprising since it has been previously reported that 
IDE facilitates keratinocyte and dendritic cell transfection, and the proteins product of 
plasmid expression, are directed to the MHC type I antigen presentation that conducts to a 
Th1 Type immune response, mentioned above. Further studies should be conducted to 
better characterize the cell mediated immune response elicited by TcVac1 vaccine when 
administered by IDE. 
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Antibodies levels were evaluated in an ELISA assay where plaques were sensitized 
with TcG2 and TcG4 recombinant proteins, independently. Antibody titers for these 
proteins can be observed in figures 2 and 3 Unexpectedly, IM administrated TcVac1 
induced very low immunoglobulin levels during the vaccination period. In comparison IDE 
administration of the vaccine induced relatively high levels of all IgG subtypes. High levels 
of immunoglobulin G production were expected, since the IDE is associated to some tissue 
damage that attracts antigen-presenting cells (dendritic cells and macrophages) to the 
injection site that promote antibody production as previously described. For both treatments 
(IDE and IM) the ratio IgG2b/IgG1 was >1 which suggests a Th type 1 skewed immune 
response, which is in accordance with the observations made by Bhatia et al. (2008) and 
Gupta and Garg, 2010; 2013 for the TcVac vaccine series [17, 27, 33]. 
Antibody production after experimental infection (60 dpi) displayed significant 
increments in all infected animals in anti-TcG2 and TcG4 IgG antibodies. However, the 
largest antibodies surges for all IgG subtypes was produced from the IDE/TcVac1 animal 
groups, indicating that antigen presenting cells were more active for IDE than for IM 
vaccinated animals. The ratio IgG2b/IgG1for both vaccine treatments switched to values <1 
as compared to vaccinated animals, indicating a switch from a Th1 to a Th2 cell type 
immune response as was previously reported by Gupta et al. (2010, 2013) for the TcVac 
vaccine series [27, 33].  
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Conclusion 
Further investigation is required to complete the study of the full protective immune 
response of TcVac1 IDE protocol, however, if the immune protective response of TcVac1 
IDE matches the TcVac2 and TcVac3 vaccination protocols it would be a more practical 
approach as a clinical vaccine, since production and purification of plasmid DNA can be 
done at a fraction of a cost of what recombinant proteins or viral vectors are produces and 
with less effort [45]. Additionally the cold chain needed for proteins and viral vector based 
vaccines to prevent degradation or inactivation, is not required for plasmid DNA. 
Therefore, these results are encouraging to perform complementary experiments to fully 
test the protective capacity of TcVac1 IDE vaccination protocols. 
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Attachments  
Tables 
Table 1: Experimental groups: Vaccination before Challenge infection with T. cruzi.  
Technique Group Mice No. 
Electroporation 1-TcVac 6 
 2-pcDNA3.1 6 
 3-No DNA 6 
Intramuscular 4-TcVAC 6 
 5-pcDNA3.1 6 
 6-No DNA 6 
TcVac1; PcDNA3.1.TcG2, PcDNA3.1.TcG4, PcDNA3.MSP35, PcDNA3.MSP45, PcDNA3.GMCSF; 
Positive Control, pcDNA3.1; No DNA, Saline solution. 
 
 
Table 2: Experimental groups: Vaccination after Challenge infection with T. cruzi. 
Technique Group Mice No. 
Electroporation 7-TcVac 6 
 8-pcDNA3.1   6 
 9-No DNA 6 
Intramuscular 10-TcVac 6 
 11-pcDNA3.1   6 
 12-No DNA 6 
TcVac1; PcDNA3.1.TcG2, PcDNA3.1.TcG4, PcDNA3.MSP35, PcDNA3.MSP45, PcDNA3.GMCSF; 
Positive Control, pcDNA3.1; No DNA, Saline solution. 
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Figures  
Figure 1: TcG2 and TcG4 recombinant proteins elicit a stronger in-vitro proliferation in 
splenocytes from TcVac1/IDE than from TcVac1/IM immunized animals before and after 
challenge infection. 
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(A) IDE mice groups’ showed higher significant differences of splenocytes response 
corresponding to TcG2 and TcG4 antigen encoding plasmids with p˂0.001 and p˂0.0001 
versus control and p˂0.05 and p˂0.001 levels versus IM, while intramuscular mice groups 
showed a lower significant difference with p˂0.05 levels for both TcG2 and TcG4 antigen 
encoding plasmids versus control. (B) IDE mice groups showed a significant high level for 
TcG2 and Tcg4 antigen encoding plasmids with p˂0.0001 for both versus control and 
p˂0.001 versus both antigen encoding plasmids versus IM mice groups. Finally, IM mice 
groups shoed a lower significant level for both antigen encoding plasmids with p˂0.001 
levels versus control. Splenocytes proliferations analysis was monitored at 495 nm using 
EPOCH microplate reader. 
 
  
Immune protection against Trypanosoma cruzi induced by TcVac1 vaccine in a murine model using an intradermal/electroporation protocol  
67 
Figure 2: rTcG2 and rTcG4 proteins elicit stronger IgG antibody levels in mice with 
intradermal electroporation than with Intramuscular injection with TcVac1, before 
challenge infection. 
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Mice were immunized with 4 vaccine boosts, 15 days after the last immunization mice sera 
were collected and analyzed by ELISA assay at (1:100) sera dilution. (A & B) Specific 
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antibody responses were measured corresponding to immunoglobulin G and IgG subtypes 
(IgG1, IgG2a, IgG2b). A higher antibody response was observed in electroporated mice 
groups versus intramuscular mice groups (P˂0.001 and p˂0.0001) in pre- and post-
infection periods. IDE versus control showed a high antibody responses with (P˂0.001 and 
p˂0.0001)while, IM versus control did not showed a lower response but not statistically 
significantly different. (C) TcG2 and TcG4 antigen-encoding plasmids Specific antibody 
response were measured for IgG, IgG2b and IgG1 respectively for IDE mice groups versus 
IM mice groups showing a significant higher responses of all compared immunoglobulins 
for IDE mice more than IM groups(P˂0.001 and p˂0.0001).  
 
Figure 3: rTcG2 and rTcG4 proteins elicit stronger IgG antibody levels in mice with 
intradermal electroporation than with Intramuscular injection with TcVac1, after challenge 
infection.  
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C- TcVAC IDE+IM Post-infection
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Mice were immunized with 4 vaccine boosts, 15 days after the last immunization mice 
were infected with T. cruzi trypomastigotes (Sylvio 10x/4) (10,000/mouse). 60 days post 
infection sera were collected and analyzed by ELISA assay at (1:100) sera dilution. (A & 
B) Specific antibody responses were measured corresponding to immunoglobulin G and 
IgG subtypes (IgG1, IgG2a, IgG2b). A higher antibody response was observed in IDE mice 
groups versus IM mice groups (P˂0.001 and p˂0.0001) in all IgG and IgG subtypes for 
TcG2 and TcG4 antigen-encoding plasmids. A significant higher response for IDE mice 
groups versus Control (P˂0.001 and p˂0.0001) and lower significant antibody responses 
(P˂0.05 and p˂0.001) for IM mice groups versus control in both TcG2 and TcG4 antigen-
encoding plasmids. (C) TcG2 and TcG4 antigen-encoding plasmids Specific antibody 
response were measured for IgG, IgG2b and IgG1 respectively for IDE versus IM mice 
groups showing a significant higher responses of all compared immunoglobulins for IDE 
vaccinated mice(P˂0.001 and p˂0.0001). 
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9. DISCUSSION  
DNA vaccination consists of the administration of a construct engineered to 
produce an antigen of interest designed to elicit immunity against pathogens or even cancer 
cells exposed to its action. Eventually, the encoded immunogen will be responsible for the 
generation of a pool of antigen-specific T cells, some of which will remain as memory cells 
for long term protection. This technology has been used for a wide range of applications, 
from laboratory tools to licensed veterinary vaccines (Kutzler, 2008). Also relevant to the 
treatment of human disease, the increasing number of clinical trials predicts the tremendous 
therapeutic potential for this approach against cancer. Moreover, DNA vaccines present 
several advantages over other vaccination strategies, among which are the relatively higher 
stability of DNA that avoids cold chain disruption issues, as well as the low price and the 
ease in producing good manufacturing practices (GMP) by the use of vaccination grade 
DNA. (Senovilla, 2013; Kutzler, 2008) 
The effectiveness of T. cruzi genes as genetic vaccines for the elicitation of 
parasite-specific immune responses has recently been shown in a number of laboratories 
with several different T. cruzi strains (Garg et al., 1997, 2005; Bhatia et al., 2004, 2008; 
Gupta et al., 2010; Vázquez-chagoyán et al., 2011; Rodrigues, 2011; Sepulveda, 2000; 
Tesoro-Cruz, 2008). The antigenic potential of TcG2 and TcG4 was shown by studies of 
our group which demonstrated that the encoded antigens elicited antibodies that bound to 
the parasite surface and exhibited trypanolytic and agglutination activities (Bolhassani, 
2011; Bhatia et al., 2008). 
Manipulation of antigen presentation and processing pathways is an important 
aspect in DNA vaccine technology. Several approaches have been studied in DNA vaccine 
designs, including: co-delivery of immune-modulatory molecules, diverse routes of 
administration or prime-boost regimens. Among the different DNA vaccine administration 
strategies reported, the use of naked plasmid DNA injected with intramuscularly (IM), the 
subcutaneously (SC), intradermally (ID) or intranasally approaches (Lai, 2009) and the 
epidermal transfection with either coated or naked DNA administered through gene gun 
(Fioretti et al., 2010). Pros and cons have been reported for alternative vaccine strategies. 
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For example: Viral mediated gene transfer by genetically modified viruses (lentiviruses, 
adenoviruses, adeno-associated viruses, and retroviruses) has high transfection efficiency 
and stability. However, disadvantages of these methods may be the production cost, 
putative toxic side effects, limited transgene size that can be used and the potential 
insertional mutagenesis that may be induced by these viral vectors, (reviewed by Fioretti et 
al., 2010). Intramuscular or intradermal injection of plasmid predominantly leads to 
transfection of myocytes or keratinocytes. However, these type of cells lack expression of 
major histocompatibility complex (MHC) class II and for that reason they do not prime T 
lymphocytes directly. It is likely that immune priming occurs through dendritic cells (DCs) 
present at the site of DNA injection or that are attracted in response to inflammatory or 
chemotactic signals following vaccination. Dendritic cells are thought to be responsible for 
antigen presentation following direct transfection of plasmid DNA, (reviewed by Fioretti et 
al., 2010). 
TcG2 and TcG4 antigens have been tested experimentally in a series of 
combinations of TcVac anti-T. cruzi candidate antigens in order to test differential 
efficacies of the vaccine preparations. Vaccines strategies tested included pcDNA-
prime/pcDNA-boost in mice and dogs (TcVac1) (Aparicio-Burgos, 2011; Gupta and Garg, 
2013), pcDNA-prime/recombinant protein boost (TcVac2) (Aparicio-Burgos, 2011), and 
pcDNA-prime/MVA boost (TcVac3) (Gupta and Garg 2013). 
TcVac1 vaccine elicited a strong Th1-type antibody response dominated by 
IgG2b/IgG1 isotypes, which were maintained after a challenge infection. Vaccinated 
animals controlled 50-90% of the acute phase tissue parasite burden. Lack of splenocyte 
proliferation of vaccinated/infected animals in vitro suggests that protection from challenge 
infection was not provided by an active T-cell response. TcVac2 vaccine also induced a 
strong IgG2b>IgG1 antibody response and a moderate level of lymphocyte proliferation in 
mice. After Challenge infection IgG2b>IgG1 antibody response expanded and elicited a 
substantial CD8+ T cell response, which is associated with type 1 cytokines (IFN-γ and 
TNF-α) that resulted in control of acute parasite burden. During chronic phase antibody 
response persisted, as well as CD8+ T cells, however IL-4/IL-10 cytokines became 
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dominant in vaccinated mice. Tissue parasitism, inflammation and fibrosis in heart and 
skeletal muscle of TcVac2-vaccinated chronic mice were undetectable by histological 
techniques, as compared to non vaccinated/infected animals which exhibited persistent 
parasite burden and immunopathology in the myocardium. TcVac3 vaccine also elicited a 
strong IgG2b>IgG1 antibody response and a robust T. cruzi-specific CD8+ T cell response 
with Type-1 cytokine (IFN-γ + TNF-α> IL-4 + IL-10) and cytolytic effector phenotype. 
TcVac3 induced significantly effector T cells upon challenge infection and provided >92% 
control of T. cruzi. In chronic phase of infection mice exhibited a significant decline (up to 
70%) in IFN-γ and CD8+ T cells a predominance of immune-regulatory IL-10/CD4+ T 
cell, and presented undetectable tissue parasitism, inflammatory infiltrate, and myocardium 
fibrosis. As a whole the experience with TcVac series vaccines suggests that a protective 
vaccine elicits a strong antibody response IgG2b>IgG1 and a robust T. cruzi-specific CD8+ 
T cell response with Type-1 cytokine (IFN-γ + TNF-α > IL-4 + IL-10) and cytolytic 
effector phenotype that even if it does not produce a sterile immunity, it does control 
parasitemia and tissue parasite burden. Then during the infection Th type 1 is switched for a 
Th type 2 immune response which is associated to a healing inflammation (Gupta and 
Garg, 2010). 
The TcVac vaccine series are designed for prime/boost doses. They all start with a 
DNA prime dose and finish with either, DNA, recombinant protein or viral vector boost. 
This difference may explain the dissimilarities found among treatments, and mainly with 
TcVac1.  
TcVac2 and TcVac3 induce a more effective immune response, however, 
production and purification of recombinant proteins or viral vectors is quite more expensive 
than plasmid DNA production and purification. Therefore we decided to test a more 
efficient way of administration of a DNA-prime/DNA-boost vaccine approach which we 
found in intradermal electroporation (IDE) vaccine administration, since it has been shown 
to be very effective in transfecting in-vivo cells with DNA vaccines and induce a high 
immune response.  
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IDE promotes Th1 and Th2 type immune responses because on one hand it 
reversibly permeabilizes the target cells enhancing the uptake and expression of the gene of 
interest (André, 2008, 2010), and since the site of IDE contains many antigen-presenting 
cells (APCs), mainly dendritic cells, that can be directly transfected during the vaccination 
process, and therefore the expressed antigen is presented in association with major 
histocompatibility complex (MHC) class I molecules, which will subsequently stimulate 
the synthesis of a pool of antigen-specific cytotoxic T lymphocytes(CTL). Furthermore, 
epitope display mediated by MHC class 1 is prone to induce both a T helper type 1 (Th1) 
response in conjunction with the generation CTLs (Dobaño, 2007; Wang, 2012), the most 
potent cytolytic effector cells. On the other hand, the tissue damage caused by the 
application of IDE causes inflammation and recruits antigen presenting cells (DCs, 
macrophages) and lymphocytes to the injection site inducing significant immune responses, 
including antibody production as well as T-cells. Furthermore, IDE can be repeatedly used 
in a prime/boost vaccine delivery strategy, since it does not induce undesirable immune 
responses against the delivery system (reviewed by Fioretti et al., 2010). 
 
Here, we tested TcVac1 vaccine that includes pcDNA3.1-TcG2 and pcDNA3.1-
TcG4 mammalian cell expression plasmids, but, in order to maximize its protective 
capacity, we did not eliminate the adjuvant cytokine genes that can help enhance the 
response to the antigen-encoding plasmid(s). GM-CSF enhances the antigen-presenting 
capability of dendritic cells and facilitates B- and T-cell-mediated immunity (Warren, 2000; 
Lin, 1995), and IL-12 enhance CD8+-T-cell activation and proliferation, and in promoting 
type 1 cytokine production (Lin, 1995; Pan, 1999; Cox, 1997). Co-administration of 
cytokine genes with T. cruzi antigen encoding plasmids have been associated to an 
increment in the level of antigen-specific CTL activity and humoral immune responses and 
provided substantially better protection from T. Cruzi (Gupta and Garg, 2010). 
In this experiment we expected that the TcVac1 vaccine, delivered through IDE, 
should induce a stronger immune response than TcVac1 administered intramuscularly. We 
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would expect an immune response more closely related to the responses found for TcVac2 
and TcVac3 immunization protocols. 
We found that splenocytes coming from IDE /vaccinated animals proliferated more 
than the splenocytes derived from IM/vaccinated animals. O.D. (optical density) readings 
for TcG2 or TcG4 recombinant protein stimulated splenocytes were 0.42, 0.50 for TcG2 
and 0.38, 0.39 for TcG4 from IDE and IM vaccinated animals, respectively. During the 
acute phase of infection (60 dpi) the splenocytes proliferated even further for all vaccinated 
groups, while the differences kept favouring splenocytes coming from IDE vaccinated mice 
with O.D. values of 1.2, 1.25 for TcG2 and 0.75, 0.08 for TcG4 from IDE and IM 
vaccinated animals, respectively. This study demonstrates that animals vaccinated with 
TcVac1 by IDE develop stronger cell immunity than animals vaccinated with IM vaccine 
administration. These results are not surprising since it has been previously reported that 
IDE facilitates keratinocyte and dendritic cell transfection, and the proteins product of 
plasmid expression, are directed to the MHC type I antigen presentation that conducts to a 
Th1 Type immune response, mentioned above. Further studies should be conducted to 
better characterize the cell mediated immune response elicited by TcVac1 vaccine when 
administered by IDE. 
Antibodies levels were evaluated in an ELISA assay where plaques were sensitized 
with TcG2 and TcG4 recombinant proteins, independently. Antibody titers for these 
proteins can be observed in figures 2 and 3 Unexpectedly, IM administrated TcVac1 
induced very low immunoglobulin levels during the vaccination period. In comparison IDE 
administration of the vaccine induced relatively high levels of all IgG subtypes. High levels 
of immunoglobulin G production were expected, since the IDE is associated to some tissue 
damage that attracts antigen-presenting cells (dendritic cells and macrophages) to the 
injection site that promote antibody production as previously described. For both treatments 
(IDE and IM) the ratio IgG2b/IgG1 was >1 which suggests a Th type 1 skewed immune 
response, which is in accordance with the observations made by Bhatia et al. (2008) and 
Gupta and Garg, 2010; 2013 for the TcVac vaccine series. 
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Antibody production after experimental infection (60 dpi) displayed significant 
increments in all infected animals in anti-TcG2 and TcG4 IgG antibodies. However, the 
largest antibodies surges for all IgG subtypes was produced from the IDE/TcVac1 animal 
groups, indicating that antigen presenting cells were more active for IDE than for IM 
vaccinated animals. The ratio IgG2b/IgG1for both vaccine treatments switched to values <1 
as compared to vaccinated animals, indicating a switch from a Th1 to a Th2 cell type 
immune response as was previously reported by Gupta et al. (2010, 2013) for the TcVac 
vaccine series.  
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10. CONCLUSION 
Further investigation is required to complete the study of the full protective 
immune response of TcVac1 IDE protocol, however, if the immune protective response of 
TcVac1 IDE matches the TcVac2 and TcVac3 vaccination protocols it would be a more 
practical approach as a clinical vaccine, since production and purification of plasmid DNA 
can be done at a fraction of a cost of what recombinant proteins or viral vectors are 
produces and with less effort (Fioretti et al., 2010). Additionally the cold chain needed for 
proteins and viral vector based vaccines to prevent degradation or inactivation, is not 
required for plasmid DNA. Therefore, these results are encouraging to perform 
complementary experiments to fully test the protective capacity of TcVac1 IDE vaccination 
protocols. 
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